uracil has been researched along with Colonic Neoplasms in 218 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Colonic Neoplasms: Tumors or cancer of the COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients with metastatic colorectal cancer." | 9.69 | Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. ( Amellal, N; Benhadji, KA; Bondarenko, I; Ciardiello, F; Cremolini, C; Cruz, FM; Elez, E; Fakih, M; Leger, C; Liposits, G; Modest, DP; Pápai, Z; Poureau, PG; Prager, GW; Stroyakovskiy, D; Tabernero, J; Taieb, J; Van Cutsem, E; Vidot, L; Wyrwicz, L, 2023) |
| "In this phase Ib study MODURATE, we optimized the dosing schedule and tested the efficacy and safety of trifluridine/tipiracil, irinotecan, and bevacizumab in patients with metastatic colorectal cancer with fluoropyrimidine and oxaliplatin treatment failure." | 9.69 | Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study. ( Ando, M; Hamauchi, S; Honda, K; Kadowaki, S; Kawakami, T; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Shirasu, H; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2023) |
| "A literature search in the Medline/PubMed and Embase databases was executed for finding series of trifluridine/tipiracil with bevacizumab in metastatic colorectal cancer." | 9.41 | A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series. ( Voutsadakis, IA, 2023) |
| "Trifluridine/tipiracil (TAS-102) has achieved modest efficacy in the late-line treatment of metastatic colorectal cancer." | 8.31 | An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study. ( Chen, B; Chen, X; He, Y; Liu, Y; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, J, 2023) |
| "Trifluridine/Tipiracil (TAS-102) and regorafenib are FDA-approved in the United States for treatment of refractory metastatic colorectal cancer (mCRC)." | 8.31 | A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. ( Florou, V; Garrido-Laguna, I; Haaland, B; Nevala-Plagemann, C; Sama, S; Shen, J; Ying, J, 2023) |
| "Although combination chemotherapy with trifluridine/tipiracil (TAS-102) and bevacizumab (BEV) is highly effective for metastatic unresectable colorectal cancer (mCRC), this combination chemotherapy often induces nausea and vomiting." | 8.31 | Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy. ( Fujii, H; Hirose, C; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Sadaka, S; Suzuki, A; Takahashi, T; Watanabe, D, 2023) |
| "The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial." | 8.31 | Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany. ( Bruch, HR; de Buhr, R; Decker, T; Frank, M; Göhler, T; Grundeis, M; Grunewald, R; Harich, HD; Hartmann, F; Hogrefe, C; Kojouharoff, G; Kröning, H; Liersch, R; Lipke, J; Marschner, N; Moorahrend, E; Nusch, A; Potthoff, K; Reisländer, T; Sauer, A; Schwaner, I; Semsek, D; Stephany, M; Uhlig, J; Vehling-Kaiser, U; Welslau, M, 2023) |
| "In the pivotal RECOURSE trial, trifluridine/tipiracil improved survival outcomes in refractory metastatic colorectal cancer (mCRC), while demonstrating an acceptable toxicity profile." | 8.31 | The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer. ( Andreozzi, V; Barros, AG; Brito-da-Silva, J; Costa, AL; Costa, L; Cruz, J; Dâmaso, S; Félix, J; Mansinho, A; Marques, D; Mota, M; Pinheiro, S; Pratas, E; Quintela, A; Rodrigues, J; Teixeira, AR, 2023) |
| "Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) are standard therapies for refractory metastatic colorectal cancer (mCRC)." | 8.31 | Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan. ( Kagawa, Y; Kunitomi, Y; Nakashima, M; Okude, R; Shinozaki, E; Tone, T, 2023) |
| "The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies." | 8.12 | Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness. ( Giuliani, J, 2022) |
| "The RECOURSE trial supported trifluridine/tipiracil as a treatment option in metastatic colorectal cancer (mCRC)." | 8.12 | The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. ( Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ, 2022) |
| "Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies." | 8.12 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". ( Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D, 2022) |
| "The combination of trifluridine-tipiracil and bevacizumab was compared with trifluridine-tipiracil monotherapy in a randomized, open-label, phase II trial, resulting in a statistically significant and clinically relevant improvement in progression-free survival (PFS), with tolerable toxicity in patients with refractory metastatic colorectal cancer (mCRC); however, evidence supporting the role of this combination in a real-world setting is limited." | 8.12 | Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer. ( Arrichiello, G; Ciardiello, D; Ciardiello, F; De Falco, V; Facchini, G; Famiglietti, V; Incoronato, P; Laterza, MM; Martinelli, E; Martini, G; Nacca, V; Napolitano, R; Napolitano, S; Nicastro, A; Paragliola, F; Perrone, A; Suarato, G; Troiani, T, 2022) |
| " Since genetic variation in taste influences vegetable preference, we tested associations between bitterness of 6-n-propylthiouracil (PROP), a measure of taste genetics, and number of colonic polyps, a measure of colon cancer risk, in 251 men who underwent screening lower endoscopy." | 7.73 | Association between 6-n-propylthiouracil (PROP) bitterness and colonic neoplasms. ( Bartoshuk, LM; Basson, MD; Dichello, SZ; Duffy, VB; Panzini, L; Weiffenbach, JM, 2005) |
| " In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)." | 7.69 | Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997) |
| "Exposure to dehydroepiandrosterone caused a concentration-dependent accumulation of HT-29 human colonic adenocarcinoma cells in S-phase and sensitization toward the cytotoxic effects of fluorouracil deoxyriboside but not 5-fluorouracil." | 7.68 | Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells. ( Holbrook, CT; Klann, RC; Nyce, J, 1990) |
| "Administration of high-dose uridine or cytidine (3500 mg/kg) resulted in severe hypothermia of 6-10 degrees C in mice." | 7.67 | Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. ( Lankelma, J; Laurensse, EJ; Leyva, A; Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1987) |
| "Colorectal cancer is a disease of older patients, but few guidelines directly address age in their recommendations." | 7.01 | Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. ( Araujo, KB; Festa, J; Mardegan, L; Meton, F; Piranda, DN; Victorino, APOS, 2023) |
| "Eniluracil and 5-FU were given with a 5-week course of preoperative radiotherapy of 4500 cGy, with a possible 540-cGy boost." | 6.71 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004) |
| "Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC." | 5.91 | Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil. ( Bebyn, M; Koper, A; Koper, K; Śledzińska, P; Wileński, S, 2023) |
| "In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients with metastatic colorectal cancer." | 5.69 | Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. ( Amellal, N; Benhadji, KA; Bondarenko, I; Ciardiello, F; Cremolini, C; Cruz, FM; Elez, E; Fakih, M; Leger, C; Liposits, G; Modest, DP; Pápai, Z; Poureau, PG; Prager, GW; Stroyakovskiy, D; Tabernero, J; Taieb, J; Van Cutsem, E; Vidot, L; Wyrwicz, L, 2023) |
| "In this phase Ib study MODURATE, we optimized the dosing schedule and tested the efficacy and safety of trifluridine/tipiracil, irinotecan, and bevacizumab in patients with metastatic colorectal cancer with fluoropyrimidine and oxaliplatin treatment failure." | 5.69 | Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study. ( Ando, M; Hamauchi, S; Honda, K; Kadowaki, S; Kawakami, T; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Shirasu, H; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2023) |
| "A literature search in the Medline/PubMed and Embase databases was executed for finding series of trifluridine/tipiracil with bevacizumab in metastatic colorectal cancer." | 5.41 | A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series. ( Voutsadakis, IA, 2023) |
| "Among these patients, 8 developed hyperbilirubinemia." | 5.33 | [Efficacy of the combined use of taurine for hyperbilirubinemia caused by UFT therapy after surgery for colonic cancer]. ( Fujii, K; Iizuka, R; Ikawa, O; Izumi, H; Kakihara, N; Katoh, Y; Matsumura, H; Miyata, K; Ohgaki, M; Shimomura, K; Shimotsuma, M; Tkenaka, A, 2006) |
| "In a randomized controlled trial conducted at a single Dublin hospital between April 2002 and March 2004, we assessed the effect of folic acid supplementation on tissue folate, uracil misincorporation into DNA, and global DNA hypomethylation in colonocytes isolated from sites of adenomatous polyps and from histologically normal tissue adjacent and 10-15 cm distal to them." | 5.22 | Folic Acid Supplementation in Postpolypectomy Patients in a Randomized Controlled Trial Increases Tissue Folate Concentrations and Reduces Aberrant DNA Biomarkers in Colonic Tissues Adjacent to the Former Polyp Site. ( Downes, CS; McGlynn, AP; McKerr, G; McNulty, H; Molloy, AM; O'Reilly, SL; Reynolds, J; Scott, JM; Strain, JJ; Ward, M; Wasson, GR; Weir, DG, 2016) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "Trifluridine/tipiracil (TAS-102) has achieved modest efficacy in the late-line treatment of metastatic colorectal cancer." | 4.31 | An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study. ( Chen, B; Chen, X; He, Y; Liu, Y; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, J, 2023) |
| "Trifluridine/tipiracil and regorafenib are indicated for metastatic colorectal cancer (mCRC) patients' refractory to standard chemotherapy." | 4.31 | TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients. ( Antista, M; Antoniotti, C; Boccaccino, A; Borelli, B; Conca, V; Cremolini, C; Crucitta, S; Cucchiara, F; Danesi, R; Del Re, M; Germani, MM; Leone, AG; Marmorino, F; Masi, G; Moretto, R; Pietrantonio, F; Provenzano, L; Rossini, D; Spagnoletti, A, 2023) |
| "Trifluridine/Tipiracil (TAS-102) and regorafenib are FDA-approved in the United States for treatment of refractory metastatic colorectal cancer (mCRC)." | 4.31 | A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. ( Florou, V; Garrido-Laguna, I; Haaland, B; Nevala-Plagemann, C; Sama, S; Shen, J; Ying, J, 2023) |
| "Although combination chemotherapy with trifluridine/tipiracil (TAS-102) and bevacizumab (BEV) is highly effective for metastatic unresectable colorectal cancer (mCRC), this combination chemotherapy often induces nausea and vomiting." | 4.31 | Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy. ( Fujii, H; Hirose, C; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Sadaka, S; Suzuki, A; Takahashi, T; Watanabe, D, 2023) |
| "The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial." | 4.31 | Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany. ( Bruch, HR; de Buhr, R; Decker, T; Frank, M; Göhler, T; Grundeis, M; Grunewald, R; Harich, HD; Hartmann, F; Hogrefe, C; Kojouharoff, G; Kröning, H; Liersch, R; Lipke, J; Marschner, N; Moorahrend, E; Nusch, A; Potthoff, K; Reisländer, T; Sauer, A; Schwaner, I; Semsek, D; Stephany, M; Uhlig, J; Vehling-Kaiser, U; Welslau, M, 2023) |
| "In the pivotal RECOURSE trial, trifluridine/tipiracil improved survival outcomes in refractory metastatic colorectal cancer (mCRC), while demonstrating an acceptable toxicity profile." | 4.31 | The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer. ( Andreozzi, V; Barros, AG; Brito-da-Silva, J; Costa, AL; Costa, L; Cruz, J; Dâmaso, S; Félix, J; Mansinho, A; Marques, D; Mota, M; Pinheiro, S; Pratas, E; Quintela, A; Rodrigues, J; Teixeira, AR, 2023) |
| "Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) are standard therapies for refractory metastatic colorectal cancer (mCRC)." | 4.31 | Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan. ( Kagawa, Y; Kunitomi, Y; Nakashima, M; Okude, R; Shinozaki, E; Tone, T, 2023) |
| "Trifluridine/tipiracil (TAS-102) is an anticancer drug for metastatic colorectal cancer (CRC)." | 4.31 | Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study. ( Doi, T; Ikeda, J; Ishikawa, T; Itoh, Y; Kirishima, T; Kudou, M; Kuriu, Y; Miyagawa, K; Nakanishi, M; Okayama, T; Otsuji, E; Takagi, T; Yoshida, N, 2023) |
| "For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival." | 4.12 | Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. ( Ananda, S; Banks, S; Dunn, C; Gard, G; Gately, L; Gibbs, P; Jalali, A; Jennens, R; Khattak, A; Kosmider, S; Lee, B; Lee, M; Lim, L; Loft, M; McKendrick, J; Shapiro, JD; Tie, J; Wong, HL; Wong, R; Yeung, JM, 2022) |
| "The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies." | 4.12 | Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness. ( Giuliani, J, 2022) |
| "The RECOURSE trial supported trifluridine/tipiracil as a treatment option in metastatic colorectal cancer (mCRC)." | 4.12 | The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. ( Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ, 2022) |
| "Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies." | 4.12 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". ( Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D, 2022) |
| "The combination of trifluridine-tipiracil and bevacizumab was compared with trifluridine-tipiracil monotherapy in a randomized, open-label, phase II trial, resulting in a statistically significant and clinically relevant improvement in progression-free survival (PFS), with tolerable toxicity in patients with refractory metastatic colorectal cancer (mCRC); however, evidence supporting the role of this combination in a real-world setting is limited." | 4.12 | Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer. ( Arrichiello, G; Ciardiello, D; Ciardiello, F; De Falco, V; Facchini, G; Famiglietti, V; Incoronato, P; Laterza, MM; Martinelli, E; Martini, G; Nacca, V; Napolitano, R; Napolitano, S; Nicastro, A; Paragliola, F; Perrone, A; Suarato, G; Troiani, T, 2022) |
| " Since genetic variation in taste influences vegetable preference, we tested associations between bitterness of 6-n-propylthiouracil (PROP), a measure of taste genetics, and number of colonic polyps, a measure of colon cancer risk, in 251 men who underwent screening lower endoscopy." | 3.73 | Association between 6-n-propylthiouracil (PROP) bitterness and colonic neoplasms. ( Bartoshuk, LM; Basson, MD; Dichello, SZ; Duffy, VB; Panzini, L; Weiffenbach, JM, 2005) |
| "One patient with pulmonary metastasis from colon cancer and one with para-aortic lymph node metastasis were treated with a combination of irinotecan and UFT." | 3.71 | [Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT]. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Saguchi, T; Suzuki, T; Yamamoto, T; Yasuda, S, 2002) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "The relationship between augmentation of cytotoxic activity of 5-fluorouracil (FUra) by l-leucovorin (l-LV) and combination schedule was investigated using human colon adenocarcinoma KM 20 C cell line." | 3.69 | [Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil]. ( Okabe, H; Takeda, S; Toko, T; Unemi, N; Yuasa, C, 1995) |
| " In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)." | 3.69 | Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997) |
| "Exposure to dehydroepiandrosterone caused a concentration-dependent accumulation of HT-29 human colonic adenocarcinoma cells in S-phase and sensitization toward the cytotoxic effects of fluorouracil deoxyriboside but not 5-fluorouracil." | 3.68 | Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells. ( Holbrook, CT; Klann, RC; Nyce, J, 1990) |
| "Administration of high-dose uridine or cytidine (3500 mg/kg) resulted in severe hypothermia of 6-10 degrees C in mice." | 3.67 | Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. ( Lankelma, J; Laurensse, EJ; Leyva, A; Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1987) |
| "Colorectal cancer is a disease of older patients, but few guidelines directly address age in their recommendations." | 3.01 | Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. ( Araujo, KB; Festa, J; Mardegan, L; Meton, F; Piranda, DN; Victorino, APOS, 2023) |
| "Patients aged 20-80 with stage II/III rectal cancer undergoing curative surgery without preoperative therapy were randomly assigned to receive UFT (500-600 mg/day on days 1-5, followed by 2 days rest) or S-1 (80-120 mg/day on days 1-28, followed by 14 days rest) for 1 year." | 2.82 | A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). ( Baba, H; Emi, Y; Hamada, C; Ikejiri, K; Kakeji, Y; Kotake, M; Maeda, K; Maehara, Y; Matsuda, C; Matsuda, H; Munemoto, Y; Murata, A; Oki, E; Saji, S; Sasaki, K; Suenaga, T; Yoshida, K, 2016) |
| " The overall incidence of adverse events (AEs) was 75." | 2.79 | Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial. ( Baba, H; Hamada, C; Kakeji, Y; Katsumata, K; Koda, K; Kodaira, S; Kondo, K; Matsuoka, J; Morita, T; Nishimura, G; Sadahiro, S; Saji, S; Sasaki, K; Sato, S; Tsuchiya, T; Usuki, H; Yamaguchi, Y, 2014) |
| " The overall incidence of adverse events (AEs) were 80% in S-1 and 74% in UFT/LV." | 2.77 | Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial. ( Boku, N; Endo, T; Ikejiri, K; Kameoka, S; Kinugasa, Y; Kotake, K; Matsubara, Y; Mochizuki, H; Mochizuki, I; Nakamoto, Y; Shinozaki, H; Sugihara, K; Takagane, A; Takahashi, K; Takahashi, Y; Takii, Y; Takiuchi, H; Tomita, N; Watanabe, M; Watanabe, T, 2012) |
| "SACURA trial is a multicenter randomized phase III study which aims to evaluate the superiority of 1-year adjuvant treatment with UFT to observation without any adjuvant treatment after surgery for stage II colon cancer in a large population, and to identify "high-risk factors of recurrence/death" in stage II colon cancer and predictors of efficacy and adverse events of the chemotherapy." | 2.77 | Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer. ( Ishiguro, M; Ishikawa, T; Kanemitsu, Y; Kotake, K; Matsui, S; Mochizuki, H; Shimada, Y; Sugihara, K; Takahashi, K; Teramukai, S; Tomita, N; Ueno, H; Uetake, H; Watanabe, M, 2012) |
| "Of the total patients, 47% had stage II colon cancer, and 53% had stage III colon cancer." | 2.72 | Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. ( Colangelo, LH; Colman, LK; Giguere, JK; Jacobs, AD; Lembersky, BC; Marshall, ME; O'Connell, MJ; Petrelli, NJ; Seay, TE; Smith, RE; Soran, A; Wieand, HS; Wolmark, N; Yothers, G, 2006) |
| "Eniluracil and 5-FU were given with a 5-week course of preoperative radiotherapy of 4500 cGy, with a possible 540-cGy boost." | 2.71 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004) |
| "A total of 760 patients with colon cancer and 669 patients with rectal cancer were entered into this randomized clinical trial (RCT)." | 2.71 | Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-flu ( Hojyo, K; Isomoto, H; Kato, T; Kodaira, S; Kunii, Y; Kunitomo, K; Niimoto, M; Nishida, O; Ohashi, Y; Takahashi, T; Tominaga, T; Watanabe, M; Yasutomi, M, 2004) |
| " cis-Diaminedichloroplatinum (cisplatin) has been reported to immunomodulate, especially when used in low dose in combination with 5-Fluorouracil (5-FU)." | 2.70 | Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer. ( Ando, K; Fukuzawa, M; Kanou, H; Kimura, T; Nagata, Y; Nezu, T; Shibata, M; Takekawa, M, 2002) |
| " Based on the feasibility and adverse reactions, the dosage of UFT should be set according to the body surface area at 375-425 mg/m2/day." | 2.69 | [Optimal dosage of UFT in a weekday-on/weekend-off schedule as a postoperative adjuvant chemotherapy for colorectal cancer]. ( Fukushima, T; Hiki, Y; Kumada, K; Makuuchi, H; Mitomi, T; Nagasaki, H; Nishiyama, K; Ohki, S; Otani, Y; Sadahiro, S; Shimada, H; Takahashi, T; Takemiya, S; Tsukikawa, S; Yamaguchi, S; Yamamura, T, 2000) |
| "In collaboration with 428 institutions nation-wide, comparative studies on the optimal daily dosage of UFT were carried out for non-curative resection cases of colorectal cancer for two years from January 1984 to December 1985." | 2.67 | [Cooperative Study of Surgical Adjuvant Chemotherapy for Colorectal Cancer (fourth report): five-year results after surgery]. ( Abe, O; Hattori, T; Inokuchi, K; Kikuchi, K; Komi, N; Kondo, T; Maehara, Y; Sugimachi, K; Taguchi, T; Uchino, J, 1993) |
| "Five-year survival was 82." | 2.67 | [Clinical effect of postoperative adjuvant chemotherapy for advanced colorectal cancer--comparisons of between tegafur (FT) and UFT]. ( Gotoda, H; Kinami, Y; Miyazaki, I; Saito, H; Takashima, S; Tomita, F; Yamaguchi, A, 1991) |
| "Trifluridine/tipiracil is an oral chemotherapeutic agent recently approved for third-line treatment of chemorefractory metastatic colorectal cancer." | 2.58 | Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. ( Cervantes, A; Moreno Vera, S; Peeters, M; Taieb, J, 2018) |
| " TPI is an inhibitor of TFD degradation enzyme thymidine phosphorylase and thus increases the bioavailability of TFD." | 2.53 | TAS-102 an Emerging Oral Fluoropyrimidine. ( Chen, J; Han, M; Saif, MW, 2016) |
| "UFT (tegafur and uracil) is an oral anticancer drug that has been developed in Japan." | 2.44 | UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction. ( Tanaka, F, 2007) |
| "In stage II colon cancer, treatment strategies are more debated." | 2.43 | [Adjuvant treatment of colorectal cancer]. ( Afchain, P; André, T; de Gramont, A; Segura, C, 2006) |
| "More than 50% of colon cancer-associated mutations in the p53 tumor suppressor gene are C-->T transitions." | 2.41 | Thymine DNA glycosylase. ( Bentele, M; Hardeland, U; Jiricny, J; Lettieri, T; Schär, P; Steinacher, R, 2001) |
| "Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC." | 1.91 | Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil. ( Bebyn, M; Koper, A; Koper, K; Śledzińska, P; Wileński, S, 2023) |
| "Records of patients with stage III colon cancer who underwent curative surgery and adjuvant chemotherapy from April 2007 and September 2014 were retrospectively reviewed." | 1.46 | Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur-Uracil Plus Leucovorin Versus Capecitabine. ( Hara, K; Ishii, T; Kondo, H; Shimizu, H; Suzuki, A; Takemoto, K; Tashiro, J; Yamaguchi, S, 2017) |
| "Trifluridine (TFT) is an antitumor component of a novel nucleoside antitumor agent, TAS-102, which consists of TFT and tipiracil hydrochloride (thymidine phosphorylase inhibitor)." | 1.42 | Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse. ( Chiba, M; Komoto, I; Kuwata, K; Nakagawa, F; Oka, H; Takeuchi, M; Yamashita, F; Yoshisue, K, 2015) |
| "We report a case of ascending colon cancer with right extra iliac lymph node metastases." | 1.42 | [A Case of Ascending Colon Cancer with Extra Iliac Lymph Node Metastases]. ( Amaya, K; Kaji, M; Kawahara, Y; Maeda, K; Shimizu, K; Terada, I; Terai, S; Watanabe, T; Yamamoto, S, 2015) |
| "Between 2002 and 2011, 333 Stage III colon cancer patients had surgery performed in our institute, and we studied 25 of them on our chemotherapy regimen." | 1.39 | [A retrospective study of UFT and oral leucovorin combination adjuvant chemotherapy for patients over 76 years old with stage III colon cancer]. ( Hanaoka, Y; Hashimoto, M; Kuroyanagi, H; Matoba, S; Moriyama, J; Toda, S; Tomizawa, K; Udagawa, H; Watanabe, G, 2013) |
| "Between 2003 and 2009, 273 stage III colon cancer patients underwent surgery in our institute, and we studied 156 of them." | 1.38 | [A retrospective study of UFT and oral leucovorin plus PSK combination adjuvant chemotherapy in patients with stage III colon cancer]. ( Hanaoka, Y; Hashimoto, M; Kumamoto, T; Kuroyanagi, H; Matoba, S; Moriyama, J; Sawada, T; Toda, S; Tomizawa, K; Udagawa, H; Watanabe, G, 2012) |
| "A 61-year-old man on hemodialysis due to chronic renal failure caused by diabetes mellitus was diagnosed as having ascending colon cancer with multiple liver metastases." | 1.38 | [A case of stage IV colon cancer effectively treated with tegafur uracil/calcium folinate in a patient on hemodialysis]. ( Kobayashi, M; Maeda, H; Okamoto, K; Takeshita, A, 2012) |
| " When chemotherapy with S-1 or UFT/LV started from the micrometastasis stage, not the advanced macroscopic metastasis stage, anti-LNM efficacy of S-1 was significantly higher than that of UFT/LV at the dosage in which antitumor activity of the two drugs against primary subcutaneous tumor was comparable." | 1.36 | Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV. ( Hirai, T; Ito, Y; Kato, T; Kodera, Y; Nakanishi, H; Nakao, A, 2010) |
| "A 78-year-old male with sigmoid colon cancer underwent sigmoidectomy." | 1.35 | [A patient in whom oral UFT/Leucovorin therapy proved markedly effective for lung metastasis after surgery for colon cancer]. ( Abe, K; Itoh, K; Kamiizumi, Y; Kawamura, N; Nakajima, Y; Okamura, M; Yokoyama, R, 2008) |
| "Thirty-three patients with rectal cancer underwent preoperative CRT." | 1.35 | Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. ( Ioue, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2009) |
| "For patients with T3N0M0 colon cancer without known risk factors, the necessity of chemotherapy has no definite consensus." | 1.35 | The necessity of chemotherapy in T3N0M0 colon cancer without risk factors. ( Cho, YB; Chun, HK; Kim, HC; Lee, WY; Yun, HR; Yun, SH, 2009) |
| "Lymph node metastasis was not found by CT scan 20 months after beginning chemotherapy." | 1.35 | [A case of effective treatment with UFT/LV chemotherapy for para-aortic lymph node metastasis from colonic cancer 8 years after colectomy]. ( Kimura, H; Takamura, H; Watanabe, K, 2009) |
| "As sodium bisulfite treatment converts unmethylated cytosine bases into uracil residues, bisulfite treated DNA is sensitive to UNG treatment." | 1.34 | Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA. ( Dietrich, D; Distler, J; Tetzner, R, 2007) |
| "The Hollow Fibre Assay (HFA) is usually applied as an early in vivo model for anti-cancer drug screening, but is potentially an excellent model for short-term in vivo pharmacodynamic studies." | 1.34 | The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. ( Peters, GJ; Prins, HJ; Temmink, OH; van Gelderop, E, 2007) |
| "Fifty-one patients with postoperative colon cancer (mean 61." | 1.33 | Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. ( Hayakawa, K; Miyake, K; Morimoto, T; Mukaihara, S; Nishino, M, 2005) |
| "A 54-year-old woman who had ascending colon cancer with multiple liver and lung metastases underwent rt." | 1.33 | [A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11]. ( Fujii, Y; Kobayashi, T; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T, 2005) |
| "Among these patients, 8 developed hyperbilirubinemia." | 1.33 | [Efficacy of the combined use of taurine for hyperbilirubinemia caused by UFT therapy after surgery for colonic cancer]. ( Fujii, K; Iizuka, R; Ikawa, O; Izumi, H; Kakihara, N; Katoh, Y; Matsumura, H; Miyata, K; Ohgaki, M; Shimomura, K; Shimotsuma, M; Tkenaka, A, 2006) |
| "Two metastatic colonic cancer patients were successfully treated by the combination therapy of UFT plus oral Leucovorin (UFT/LV)." | 1.33 | [Two metastatic colonic cancer patients successfully treated by combination therapy of tegafur/uracil (UFT) and oral Leucovorin]. ( Ando, T; Goto, H; Ina, K; Inagaki, J; Ito, A; Kataoka, T; Kato, H; Nagao, S; Niwa, Y; Ohkita, T, 2006) |
| "A 54-year-old man with colon cancer underwent hemicolectomy." | 1.32 | Therapy-related erythroleukemia caused by the administration of UFT and mitomycin C in a patient with colon cancer. ( Miyazaki, M; Nakamori, Y; Shinohara, K; Taguchi, A; Tominaga, T, 2003) |
| " Pharmacokinetic modulating chemotherapy (PMC) was performed after the operation." | 1.32 | [A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy]. ( Futamura, N; Matsutomo, M; Sakamoto, K; Tateyama, K; Yasumura, M, 2003) |
| " He was treated with pharmacokinetic modulating chemotherapy (PMC) and low-dose CPT-11." | 1.32 | [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11]. ( Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H, 2004) |
| " Our hypothesis was that a relatively short and high dosage of TAS-102 results in an additional mechanism of FTD incorporation into DNA other than thymidylate synthase (TS) inhibition." | 1.32 | A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. ( Emura, T; Fukushima, M; Ohshimo, H; Suzuki, N; Yamaguchi, M, 2004) |
| "Diarrhea was the major adverse effect of UFT/LV that made patients reduce dosage." | 1.31 | Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer. ( Chen, JS; Hsu, KC; Tang, R; Wang, JY; Yang, TS, 2002) |
| " Administration of modified pharmacokinetic modulating chemotherapy (PMC) using Leucovorin (intravenous infusion of 5-FU, 600 mg/m2/24 hours; oral administration of UFT, Taiho Pharmaceutical Co." | 1.31 | [A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin]. ( Hatada, T; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Ojima, E, 2002) |
| "However, the sensitivity to the micrometastases was high." | 1.31 | Experimental postoperative adjuvant chemotherapy by UFT using primary tumor amputation model. ( Fujioka, A; Fukushima, M; Nakano, K; Okabe, H; Saito, H; Sato, K; Takechi, T; Takeda, S; Uchida, J; Unemi, N, 2000) |
| "We encountered a case of unresectable colon cancer that disappeared following pharmacokinetic modulating chemotherapy (PMC)." | 1.31 | [A case report of unresectable colon cancer that disappeared following pharmacokinetic modulation chemotherapy (PMC)]. ( Asahara, T; Nakahara, H; Nakahara, M; Okajima, M; Yano, M, 2000) |
| "For cases of liver metastasis from colon cancer that are non-resectable due to multiple liver metastases, other organ metastases (lung, bone, brain etc." | 1.31 | [Three cases of liver metastasis of colon cancer responding to systemic combination chemotherapy utilizing CPT-11]. ( Kobayashi, A; Yamaguchi, M, 2000) |
| "Tegafur is a prodrug that is converted to 5-fluorouracil (5-FU) and has been reported to be less toxic and to have a higher therapeutic index." | 1.31 | Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience. ( Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Hsu, TC; Jiang, JK; Lin, JK; Lin, TC; Liu, JH; Wang, HS; Wang, WS; Yang, SH; Yen, CC, 2000) |
| "A total of 18 patients (13: colon cancer, 5: gastric cancer) with multiple liver metastases (H3) underwent hepatic arterial infusion chemotherapy (HAI) using an implanted arterial port with portable syringe pumps in our outpatient clinic." | 1.31 | [Outcomes of home anti-cancer chemotherapy--estimation of hepatic arterial infusion chemotherapy for patients with multiple liver metastases]. ( Fukunaga, M; Goda, F; Maeba, T; Maeta, H; Mihara, T; Mori, S; Ohkawa, M; Okada, H; Okano, K; Senda, S; Uchida, Y; Usuki, H; Wakabayashi, H, 2000) |
| "A case of haemolytic anaemia in a patient under treatment with UFT for metastatic colon cancer is reported." | 1.31 | UFT-induced haemolytic anaemia. ( Español, I; Fernández Ortega, A; Navarro Garcia, M; Zurita Saavedra, AJ, 2001) |
| "Human colon cancer cells (KM12SM) were injected into the cecal wall of the nude rats." | 1.31 | [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats]. ( Akagi, Y; Kobayashi, H; Matono, K; Miyagi, Y; Nakagawa, M; Nozoe, Y; Ogata, Y; Sasatomi, T; Shirouzu, K, 2001) |
| " Pharmacokinetic studies revealed that 1 h after 400 mg/kg EtdUrd administration - i." | 1.30 | 5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil. ( Erdélyi-Tóth, V; Jeney, A; Katona, C; Kovács, P; Kralovánszky, J; Noordhuis, P; Otvös, L; Pandi, E; Peters, GJ; Van der Wilt, CL, 1999) |
| "Thirty-nine patients with gastric or colonic cancer were given preoperative chemotherapy with UFT (an admixture of tegafur and uracil)." | 1.29 | Effects of preoperative chemotherapy on DNA ploidy patterns, cell cycle, and histological findings in gastric and colonic cancer patients. ( Arizono, S; Kajiura, N; Konishi, T; Kubota, K; Makuuchi, M; Nakao, K; Oka, T; Teruya, M; Tsushima, H, 1994) |
| " 5-FU oral bioavailability was approximately 100% in rats pretreated with 5-EU." | 1.29 | 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. ( Baccanari, DP; Davis, ST; Knick, VC; Spector, T, 1993) |
| "Effects of 5-fluorouracil (5-FU) and UFT on an experimental liver metastasis model were compared at equi-effective dosage levels against subcutaneous tumor of mouse colon 26." | 1.29 | Effect of 5-fluorouracil and UFT on experimental liver metastasis model of colorectal cancer using mouse colon 26 cells. ( Kosaki, G; Kurihara, M; Tominaga, T; Yoshida, Y, 1993) |
| "To evaluate the effect of the oral fluoropyrimidines, tegafur and uracil (UFT) and 5-fluorouracil (5-FU), a pharmacodynamic analysis was conducted using a nude mouse system and patients." | 1.29 | A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer. ( Hishinuma, S; Ikeda, T; Inada, T; Kotake, K; Koyama, Y; Kubota, T; Ogata, Y; Ozawa, I; Shimizu, H, 1993) |
| "Tegafur or UFT was administrated orally to patients with gastric or colorectal cancers after surgery for at least a year." | 1.29 | [Evaluation of long-term administration of oral anti-cancer agent]. ( Sakakibara, N; Watanabe, H, 1993) |
| "injection against mouse colon cancer, colon 26." | 1.28 | [Antitumor activity of T-506, a novel synthetic FUDR derivative, on murine colon cancer and its hepatic metastasis]. ( Fujimaki, M; Kurokawa, M; Kuroki, Y; Ochiai, H; Okamoto, M; Tazawa, K; Yamashita, I, 1991) |
| "5-FU concentration in liver cancer lesion was 0." | 1.28 | [Tissue UFT distribution and histological changes following UFT administration in metastatic liver cancer cases]. ( Amemiya, A; Emoto, T; Fujii, M; Han, N; Itou, A; Iwasaki, T; Tsujimura, T; Yoshikawa, K, 1990) |
| "Thirty four patients with advanced gastric cancer (GC), colon cancer (CC) biliary tract cancer (BC) and pancreatic cancer (PC) were treated with a combined chemotherapy of UFT with ADM (UFT-A), or UFT with ADM and CDDP (UFT-AC)." | 1.28 | [Combination chemotherapy of UFT with adriamycin (ADM) and cisplatin (CDDP) for advanced gastrointestinal cancer]. ( Koda, K; Kure, T; Matsunaga, T; Miyazaki, E; Morii, K; Morita, K; Nakajima, K; Nakazawa, O; Terada, S; Tsuji, Y, 1990) |
| "In 14 gastric cancer and 15 colonic cancer cases, to which UFT 400 mg/day and OK-432 2KE 2/W were administered orally and intra-muscularly for 2 weeks preoperatively until surgical treatment, intratumor 5-fluorouracil (5-FU) concentration was measured and compared with that of patients who given UFT 400 mg/day orally for 2 weeks (15 gastric cancer and 15 colonic cancer cases)." | 1.28 | [Influence of OK-432 on intratumor 5-fluorouracil concentration in cases given UFT]. ( Hosoi, H; Kitagawa, M; Sinmyo, K; Susaki, H; Suwa, H; Yamaguchi, K, 1989) |
| "Tegafur (FT) is a masked compound of 5-fluorouracil (5-FU) and supposed to be activated in the liver." | 1.28 | [Anti-tumor effect of fluoropyrimidines on human tumor cell lines transplanted in nude mice with CCl4-induced liver dysfunction]. ( Imai, S; Nio, Y; Ohgaki, K; Shiraishi, T; Tobe, T, 1989) |
| "Preoperative total doses of UFT for gastric cancer were 3." | 1.27 | [Effects of preoperative administration of UFT in gastrointestinal cancer]. ( Kagaya, H; Matsuoka, S; Miyata, S; Nagabuchi, E; Sato, Y; Uchino, J; Une, Y; Yakura, Y, 1986) |
| " However, increase in tegafur dosage volume did not correlate with 5-FU levels." | 1.27 | [5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur]. ( Arima, S; Futami, K; Kinashi, M; Shigeta, M; Shimura, H, 1986) |
| "A chemosensitivity test for UFT and FT-207, which are used in long-term administration clinically, was investigated for prediction of clinical response." | 1.27 | [In vivo chemosensitivity test for UFT and FT-207. I--Subrenal capsule assay]. ( Hattori, T; Hirabayashi, N; Niimi, K; Niimoto, M; Nishiyama, M; Nosoh, Y; Tohge, T; Yamaguchi, M, 1987) |
| " UFT inhibited significantly the tumor growth of CH-I established from colon cancer in which the prolongation of life span has been obtained by clinical long-term administration of UFT." | 1.27 | [In vivo chemosensitivity test for UFT and FT-207. II. Chemosensitivity test on human tumor xenografts transplanted in nude mice]. ( Hattori, T; Hirabayashi, N; Niimi, K; Niimoto, M; Nishiyama, M; Nosoh, Y; Toge, T; Wang, DC; Yamaguchi, M, 1987) |
| "These were; EH-1 established from esophageal cancer, SH-6 from gastric cancer and CH-3 from colon cancer." | 1.27 | Combined effects of UFT with other anticancer agents using in vivo chemosensitivity tests. ( Hattori, T; Hirabayashi, N; Niimi, K; Niimoto, M; Nishiyama, M; Saeki, T; Takagami, S; Wang, DC; Yamaguchi, M; Yoshinaka, K, 1988) |
| "Fifteen patients with stomach cancer and colorectal cancer were orally administered 600 mg of UFT before operation and the concentration of tegafur, 5-fluorouracil (5-FU) and uracil in the tissues and serum were measured by chemical assay." | 1.27 | [The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT]. ( Kikuchi, K; Kunii, Y; Mori, Y; Nitta, A; Saitou, T; Takahashi, N, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (16.06) | 18.7374 |
| 1990's | 48 (22.02) | 18.2507 |
| 2000's | 63 (28.90) | 29.6817 |
| 2010's | 45 (20.64) | 24.3611 |
| 2020's | 27 (12.39) | 2.80 |
| Authors | Studies |
|---|---|
| Jalali, A | 1 |
| Gard, G | 1 |
| Banks, S | 1 |
| Dunn, C | 1 |
| Wong, HL | 1 |
| Wong, R | 1 |
| Lee, M | 1 |
| Gately, L | 1 |
| Loft, M | 1 |
| Shapiro, JD | 1 |
| Kosmider, S | 1 |
| Tie, J | 1 |
| Ananda, S | 1 |
| Yeung, JM | 1 |
| Jennens, R | 1 |
| Lee, B | 1 |
| McKendrick, J | 1 |
| Lim, L | 1 |
| Khattak, A | 1 |
| Gibbs, P | 1 |
| Giuliani, J | 1 |
| Sadahiro, S | 6 |
| Sakamoto, K | 3 |
| Tsuchiya, T | 3 |
| Takahashi, T | 5 |
| Ohge, H | 1 |
| Sato, T | 2 |
| Kondo, K | 3 |
| Ogata, Y | 3 |
| Baba, H | 4 |
| Itabashi, M | 2 |
| Ikeda, M | 2 |
| Hamada, M | 2 |
| Maeda, K | 4 |
| Masuko, H | 1 |
| Takahashi, K | 6 |
| Sakamoto, J | 1 |
| Kusano, M | 1 |
| Hyodo, I | 2 |
| Taguri, M | 1 |
| Morita, S | 1 |
| Sousa, MJ | 1 |
| Gomes, I | 1 |
| Pereira, TC | 1 |
| Magalhães, J | 1 |
| Basto, R | 1 |
| Paulo, J | 1 |
| Jacinto, P | 1 |
| Bonito, N | 1 |
| Sousa, G | 1 |
| Coutzac, C | 1 |
| Trouilloud, I | 1 |
| Artru, P | 1 |
| Henriques, J | 1 |
| Masson, T | 1 |
| Doat, S | 1 |
| Bouché, O | 1 |
| Coriat, R | 1 |
| Saint, A | 1 |
| Moulin, V | 1 |
| Vernerey, D | 1 |
| Gallois, C | 1 |
| De La Fouchardière, C | 1 |
| Tougeron, D | 1 |
| Taieb, J | 3 |
| Yoshino, T | 4 |
| Van Cutsem, E | 5 |
| Li, J | 2 |
| Shen, L | 1 |
| Kim, TW | 2 |
| Sriuranpong, V | 1 |
| Xuereb, L | 1 |
| Aubel, P | 1 |
| Fougeray, R | 1 |
| Cattan, V | 1 |
| Amellal, N | 2 |
| Ohtsu, A | 4 |
| Mayer, RJ | 1 |
| Martínez-Lago, N | 1 |
| Chucla, TC | 1 |
| De Castro, BA | 1 |
| Ponte, RV | 1 |
| Rendo, CR | 1 |
| Rodriguez, MIG | 1 |
| Diaz, SS | 1 |
| Suarez, BG | 1 |
| de la Cámara Gomez, J | 1 |
| Fernández, FB | 1 |
| Salvador, MM | 1 |
| Lopez, MR | 1 |
| Arrichiello, G | 1 |
| Perrone, A | 1 |
| Napolitano, S | 1 |
| Martini, G | 1 |
| De Falco, V | 1 |
| Incoronato, P | 1 |
| Laterza, MM | 1 |
| Facchini, G | 1 |
| Famiglietti, V | 1 |
| Nacca, V | 1 |
| Paragliola, F | 1 |
| Napolitano, R | 1 |
| Suarato, G | 1 |
| Nicastro, A | 1 |
| Martinelli, E | 1 |
| Ciardiello, D | 1 |
| Ciardiello, F | 2 |
| Troiani, T | 1 |
| Hochster, H | 3 |
| Shitara, K | 3 |
| Mayer, R | 3 |
| Falcone, A | 3 |
| Doi, T | 4 |
| Ilson, DH | 3 |
| Arkenau, HT | 3 |
| George, B | 3 |
| Benhadji, KA | 4 |
| Makris, L | 3 |
| Tabernero, J | 4 |
| Nie, C | 1 |
| Xu, W | 1 |
| Chen, B | 1 |
| Lv, H | 1 |
| Wang, J | 2 |
| Liu, Y | 1 |
| He, Y | 1 |
| Wang, S | 1 |
| Zhao, J | 1 |
| Chen, X | 1 |
| Borelli, B | 1 |
| Crucitta, S | 1 |
| Boccaccino, A | 1 |
| Antista, M | 1 |
| Antoniotti, C | 1 |
| Marmorino, F | 1 |
| Rossini, D | 1 |
| Conca, V | 1 |
| Germani, MM | 1 |
| Provenzano, L | 1 |
| Spagnoletti, A | 1 |
| Leone, AG | 1 |
| Cucchiara, F | 1 |
| Pietrantonio, F | 1 |
| Del Re, M | 1 |
| Danesi, R | 1 |
| Masi, G | 1 |
| Cremolini, C | 2 |
| Moretto, R | 1 |
| Chen, PH | 1 |
| Jhou, HJ | 1 |
| Chung, CH | 1 |
| Wu, YY | 1 |
| Huang, TC | 1 |
| Lee, CH | 1 |
| Chien, WC | 1 |
| Chen, JH | 2 |
| Nevala-Plagemann, C | 1 |
| Sama, S | 1 |
| Ying, J | 1 |
| Shen, J | 1 |
| Haaland, B | 1 |
| Florou, V | 1 |
| Garrido-Laguna, I | 1 |
| Victorino, APOS | 1 |
| Meton, F | 1 |
| Mardegan, L | 1 |
| Festa, J | 1 |
| Piranda, DN | 1 |
| Araujo, KB | 1 |
| Matsuoka, S | 3 |
| Fujii, H | 1 |
| Iihara, H | 1 |
| Ohata, K | 1 |
| Hirose, C | 1 |
| Watanabe, D | 1 |
| Sadaka, S | 1 |
| Kiyama, S | 1 |
| Makiyama, A | 2 |
| Kobayashi, R | 1 |
| Matsuhashi, N | 1 |
| Suzuki, A | 3 |
| Prager, GW | 1 |
| Fakih, M | 1 |
| Elez, E | 1 |
| Cruz, FM | 1 |
| Wyrwicz, L | 1 |
| Stroyakovskiy, D | 1 |
| Pápai, Z | 1 |
| Poureau, PG | 1 |
| Liposits, G | 1 |
| Bondarenko, I | 1 |
| Modest, DP | 1 |
| Leger, C | 1 |
| Vidot, L | 1 |
| Kröning, H | 1 |
| Göhler, T | 1 |
| Decker, T | 1 |
| Grundeis, M | 1 |
| Kojouharoff, G | 1 |
| Lipke, J | 1 |
| Semsek, D | 1 |
| Moorahrend, E | 1 |
| Sauer, A | 1 |
| Bruch, HR | 1 |
| Liersch, R | 1 |
| Nusch, A | 1 |
| Vehling-Kaiser, U | 1 |
| Welslau, M | 1 |
| Grunewald, R | 1 |
| Harich, HD | 1 |
| Stephany, M | 1 |
| Uhlig, J | 1 |
| de Buhr, R | 1 |
| Frank, M | 1 |
| Hogrefe, C | 1 |
| Marschner, N | 1 |
| Potthoff, K | 1 |
| Hartmann, F | 1 |
| Reisländer, T | 1 |
| Schwaner, I | 1 |
| Taniguchi, H | 1 |
| Yamazaki, K | 2 |
| Masuishi, T | 2 |
| Kawakami, T | 1 |
| Onozawa, Y | 1 |
| Honda, K | 1 |
| Kadowaki, S | 1 |
| Narita, Y | 1 |
| Tsushima, T | 1 |
| Hamauchi, S | 1 |
| Todaka, A | 1 |
| Yokota, T | 1 |
| Ando, M | 1 |
| Mori, K | 1 |
| Shirasu, H | 1 |
| Yasui, H | 1 |
| Muro, K | 2 |
| Koper, A | 1 |
| Wileński, S | 1 |
| Śledzińska, P | 1 |
| Bebyn, M | 1 |
| Koper, K | 1 |
| Voutsadakis, IA | 1 |
| Marques, D | 1 |
| Costa, AL | 1 |
| Mansinho, A | 1 |
| Quintela, A | 1 |
| Pratas, E | 1 |
| Brito-da-Silva, J | 1 |
| Cruz, J | 1 |
| Félix, J | 1 |
| Rodrigues, J | 1 |
| Mota, M | 1 |
| Teixeira, AR | 1 |
| Dâmaso, S | 1 |
| Pinheiro, S | 1 |
| Andreozzi, V | 1 |
| Costa, L | 1 |
| Barros, AG | 1 |
| Kagawa, Y | 1 |
| Shinozaki, E | 1 |
| Okude, R | 1 |
| Tone, T | 1 |
| Kunitomi, Y | 1 |
| Nakashima, M | 1 |
| Yoshida, N | 1 |
| Kuriu, Y | 1 |
| Ikeda, J | 1 |
| Kudou, M | 1 |
| Kirishima, T | 1 |
| Okayama, T | 1 |
| Miyagawa, K | 1 |
| Takagi, T | 1 |
| Nakanishi, M | 1 |
| Ishikawa, T | 4 |
| Itoh, Y | 2 |
| Otsuji, E | 1 |
| Shiroyama, M | 1 |
| Fukuoka, S | 1 |
| Takashima, A | 1 |
| Kumekawa, Y | 1 |
| Kajiwara, T | 1 |
| Shimada, Y | 3 |
| Esaki, T | 1 |
| Moriwaki, T | 1 |
| Catala, GN | 1 |
| Bestwick, CS | 1 |
| Russell, WR | 1 |
| Tortora, K | 1 |
| Giovannelli, L | 1 |
| Moyer, MP | 1 |
| Lendoiro, E | 1 |
| Duthie, SJ | 1 |
| Chen, J | 2 |
| Lin, H | 1 |
| Peng, Y | 1 |
| Shigematsu, N | 1 |
| Kawashiri, T | 1 |
| Kobayashi, D | 1 |
| Shimizu, S | 1 |
| Mine, K | 1 |
| Hiromoto, S | 1 |
| Uchida, M | 1 |
| Egashira, N | 1 |
| Shimazoe, T | 1 |
| Court, OR | 1 |
| Shemilt, K | 1 |
| Huang, WY | 1 |
| Ho, CL | 1 |
| Lee, CC | 2 |
| Hsiao, CW | 2 |
| Wu, CC | 2 |
| Jao, SW | 2 |
| Yang, JF | 1 |
| Lo, CH | 1 |
| Baba, Y | 1 |
| Tamura, T | 2 |
| Satoh, Y | 1 |
| Gotou, M | 1 |
| Sawada, H | 1 |
| Ebara, S | 1 |
| Shibuya, K | 1 |
| Soeda, J | 1 |
| Nakamura, K | 2 |
| Matsuda, C | 3 |
| Ishiguro, M | 5 |
| Teramukai, S | 3 |
| Kajiwara, Y | 1 |
| Fujii, S | 1 |
| Kinugasa, Y | 3 |
| Nakamoto, Y | 4 |
| Kotake, M | 3 |
| Sakamoto, Y | 3 |
| Kurachi, K | 2 |
| Maeda, A | 1 |
| Komori, K | 1 |
| Tomita, N | 5 |
| Kotake, K | 5 |
| Watanabe, M | 5 |
| Mochizuki, H | 4 |
| Nakagawa, Y | 1 |
| Sugihara, K | 6 |
| Peeters, M | 1 |
| Cervantes, A | 1 |
| Moreno Vera, S | 1 |
| Hayashi, M | 1 |
| Terai, S | 2 |
| Okamoto, K | 3 |
| Sakai, S | 1 |
| Kinoshita, J | 1 |
| Hayashi, H | 1 |
| Oyama, K | 1 |
| Miyashita, T | 1 |
| Inokuchi, M | 1 |
| Tajima, H | 1 |
| Takamura, H | 2 |
| Ninomiya, I | 1 |
| Fushida, S | 1 |
| Ohta, T | 3 |
| Ueno, H | 2 |
| Nakatani, E | 2 |
| Uetake, H | 2 |
| Egawa, T | 1 |
| Yasumasa, K | 1 |
| Murata, K | 2 |
| Ikawa, O | 2 |
| Shinji, S | 1 |
| Murotani, K | 1 |
| Matsui, S | 2 |
| Carriles, C | 1 |
| Jimenez-Fonseca, P | 1 |
| Sánchez-Cánovas, M | 1 |
| Pimentel, P | 1 |
| Carmona-Bayonas, A | 1 |
| García, T | 1 |
| Carbajales-Álvarez, M | 1 |
| Lozano-Blázquez, A | 1 |
| Benson, AB | 1 |
| Tomizawa, K | 2 |
| Hanaoka, Y | 2 |
| Toda, S | 2 |
| Moriyama, J | 2 |
| Matoba, S | 2 |
| Kuroyanagi, H | 2 |
| Hashimoto, M | 3 |
| Udagawa, H | 2 |
| Watanabe, G | 2 |
| Yoh, T | 1 |
| Wada, S | 1 |
| Kobayashi, A | 2 |
| Nakamura, Y | 4 |
| Kato, T | 4 |
| Nakayama, H | 1 |
| Okamura, R | 1 |
| MacFarlane, AJ | 2 |
| McEntee, MF | 2 |
| Stover, PJ | 2 |
| Tsuchiya, N | 1 |
| Yamagishi, S | 1 |
| Ishibe, A | 1 |
| Matsuo, K | 2 |
| Misuta, K | 1 |
| Nakano, A | 1 |
| Sasaki, K | 4 |
| Katsumata, K | 2 |
| Nishimura, G | 2 |
| Kakeji, Y | 3 |
| Morita, T | 3 |
| Koda, K | 4 |
| Sato, S | 2 |
| Matsuoka, J | 2 |
| Yamaguchi, Y | 2 |
| Usuki, H | 3 |
| Hamada, C | 4 |
| Kodaira, S | 3 |
| Saji, S | 2 |
| Tashiro, J | 2 |
| Yamaguchi, S | 4 |
| Ishii, T | 3 |
| Kondo, H | 2 |
| Morita, Y | 1 |
| Hara, K | 2 |
| Koyama, I | 1 |
| Yoshida, M | 2 |
| Ikejiri, K | 3 |
| Mochizuki, I | 2 |
| Takagane, A | 2 |
| Endo, T | 2 |
| Shinozaki, H | 2 |
| Takii, Y | 2 |
| Kameoka, S | 3 |
| Watanabe, T | 3 |
| Boku, N | 2 |
| Tanaka, N | 1 |
| Okabe, H | 6 |
| Fujioka, A | 5 |
| Yamamura, K | 1 |
| Nakagawa, F | 2 |
| Nagase, H | 1 |
| Yokogawa, T | 1 |
| Oguchi, K | 1 |
| Ishida, K | 1 |
| Osada, A | 1 |
| Kazuno, H | 1 |
| Yamada, Y | 4 |
| Abali, H | 1 |
| Yavuz, S | 1 |
| Calıkusu, Z | 1 |
| Seyrek, E | 1 |
| Lee, HJ | 1 |
| Oh, SJ | 1 |
| Lee, EJ | 1 |
| Chung, JH | 1 |
| Kim, Y | 1 |
| Ryu, JS | 1 |
| Kim, SY | 1 |
| Lee, SJ | 1 |
| Moon, DH | 1 |
| Hiratsuka, M | 2 |
| Yamashita, H | 1 |
| Akai, F | 1 |
| Hosono, H | 1 |
| Hishinuma, E | 1 |
| Hirasawa, N | 1 |
| Mori, T | 2 |
| Yamashita, F | 1 |
| Komoto, I | 1 |
| Oka, H | 2 |
| Kuwata, K | 1 |
| Takeuchi, M | 1 |
| Yoshisue, K | 1 |
| Chiba, M | 1 |
| Han, M | 1 |
| Saif, MW | 2 |
| Terada, I | 1 |
| Kawahara, Y | 1 |
| Amaya, K | 1 |
| Yamamoto, S | 1 |
| Kaji, M | 1 |
| Shimizu, K | 1 |
| Oki, E | 2 |
| Murata, A | 2 |
| Yoshida, K | 1 |
| Munemoto, Y | 1 |
| Suenaga, T | 1 |
| Matsuda, H | 1 |
| Emi, Y | 1 |
| Maehara, Y | 4 |
| O'Reilly, SL | 1 |
| McGlynn, AP | 1 |
| McNulty, H | 1 |
| Reynolds, J | 1 |
| Wasson, GR | 1 |
| Molloy, AM | 1 |
| Strain, JJ | 1 |
| Weir, DG | 1 |
| Ward, M | 1 |
| McKerr, G | 1 |
| Scott, JM | 1 |
| Downes, CS | 1 |
| Hu, JM | 1 |
| Chou, YC | 1 |
| Chen, CT | 1 |
| Hu, SI | 1 |
| Liu, WT | 1 |
| Shimizu, H | 3 |
| Takemoto, K | 1 |
| Okamura, M | 1 |
| Kamiizumi, Y | 1 |
| Kawamura, N | 1 |
| Yokoyama, R | 2 |
| Itoh, K | 1 |
| Abe, K | 1 |
| Nakajima, Y | 1 |
| Tomimatsu, H | 1 |
| Nakano, T | 1 |
| Sohn, KJ | 1 |
| Jang, H | 1 |
| Campan, M | 1 |
| Weisenberger, DJ | 1 |
| Dickhout, J | 1 |
| Wang, YC | 1 |
| Cho, RC | 1 |
| Yates, Z | 1 |
| Lucock, M | 1 |
| Chiang, EP | 1 |
| Austin, RC | 1 |
| Choi, SW | 1 |
| Laird, PW | 1 |
| Kim, YI | 1 |
| Saigusa, S | 1 |
| Tanaka, K | 1 |
| Toiyama, Y | 1 |
| Yokoe, T | 1 |
| Okugawa, Y | 1 |
| Ioue, Y | 1 |
| Miki, C | 2 |
| Kusunoki, M | 2 |
| Yun, HR | 1 |
| Kim, HC | 1 |
| Lee, WY | 1 |
| Cho, YB | 1 |
| Yun, SH | 1 |
| Chun, HK | 1 |
| Shindo, Y | 1 |
| Tenma, K | 1 |
| Okuyama, M | 1 |
| Hibino, M | 1 |
| Sasaki, Y | 1 |
| Kitamura, T | 1 |
| Nakamura, M | 1 |
| Kimura, H | 1 |
| Watanabe, K | 1 |
| Takashima, T | 1 |
| Tayama, Y | 1 |
| Hirata, K | 2 |
| Ito, Y | 1 |
| Nakanishi, H | 1 |
| Kodera, Y | 1 |
| Hirai, T | 1 |
| Nakao, A | 1 |
| Mounier-Boutoille, H | 1 |
| Boisdron-Celle, M | 1 |
| Cauchin, E | 1 |
| Galmiche, JP | 1 |
| Morel, A | 1 |
| Gamelin, E | 1 |
| Matysiak-Budnik, T | 1 |
| Perry, CA | 1 |
| Lin, DM | 1 |
| Yoshioka, S | 1 |
| Wakatsuki, K | 1 |
| Kataoka, M | 1 |
| Tonooka, T | 1 |
| Miyazawa, K | 1 |
| Suzuki, D | 1 |
| Furukawa, A | 1 |
| Oeda, Y | 1 |
| Lin, BR | 1 |
| Lai, HS | 1 |
| Chang, TC | 1 |
| Lee, PH | 1 |
| Chang, KJ | 1 |
| Liang, JT | 1 |
| Narita, T | 1 |
| Seshimo, A | 1 |
| Aratake, K | 1 |
| Ogawa, S | 1 |
| Hirosawa, T | 1 |
| Hashimoto, T | 2 |
| Amano, K | 1 |
| Murayama, R | 1 |
| Nagata, N | 1 |
| Honda, S | 2 |
| Fujii, M | 4 |
| Sawatsubashi, T | 1 |
| Shinohara, I | 1 |
| Kuroda, H | 1 |
| Sako, T | 1 |
| Sanefuji, H | 1 |
| Nishigaki, T | 1 |
| Mikami, K | 1 |
| Koyama, M | 1 |
| Morohashi, H | 1 |
| Tsutsumi, S | 1 |
| Yonaiyama, S | 1 |
| Hakamada, K | 1 |
| Takiuchi, H | 1 |
| Takahashi, Y | 5 |
| Matsubara, Y | 1 |
| Teraishi, F | 1 |
| Ozaki, K | 1 |
| Shibuya, Y | 1 |
| Shima, Y | 1 |
| Nakamura, T | 1 |
| Fukui, Y | 1 |
| Nishioka, Y | 1 |
| Horimi, T | 1 |
| Uchida, Y | 2 |
| Kumamoto, T | 1 |
| Sawada, T | 1 |
| Kanemitsu, Y | 2 |
| Kobayashi, M | 2 |
| Maeda, H | 1 |
| Takeshita, A | 1 |
| Yang, TS | 1 |
| Wang, JY | 1 |
| Tang, R | 1 |
| Hsu, KC | 1 |
| Chen, JS | 1 |
| Inoue, Y | 1 |
| Ojima, E | 1 |
| Hatada, T | 1 |
| Suzuki, T | 2 |
| Ishikawa, K | 1 |
| Maeda, Y | 2 |
| Saguchi, T | 1 |
| Yasuda, S | 1 |
| Makuuchi, H | 2 |
| Murayama, C | 1 |
| Yamamoto, T | 1 |
| Ishida, H | 2 |
| Takeuchi, I | 1 |
| Ohsawa, T | 1 |
| Nakada, H | 1 |
| Ishizuka, N | 1 |
| Yokoyama, M | 1 |
| Inokuma, S | 1 |
| Yamada, H | 1 |
| Odaka, A | 1 |
| Hoshino, T | 1 |
| Murata, N | 2 |
| Hashimoto, D | 1 |
| Matsumoto, Y | 1 |
| Miura, T | 1 |
| Nakamori, Y | 2 |
| Miyazaki, M | 1 |
| Tominaga, T | 3 |
| Taguchi, A | 1 |
| Shinohara, K | 2 |
| Mayor, S | 1 |
| CURRERI, AR | 1 |
| ANSFIELD, FJ | 1 |
| SHARP, GS | 1 |
| BENEFIEL, WW | 1 |
| DALMAUCIRIA, M | 1 |
| ZIMMERMAN, M | 1 |
| SEIDENBERG, J | 1 |
| Futamura, N | 1 |
| Matsutomo, M | 1 |
| Yasumura, M | 1 |
| Tateyama, K | 1 |
| Sasaki, E | 1 |
| Sasaki, T | 2 |
| Czito, BG | 1 |
| Hong, TJ | 1 |
| Cohen, DP | 1 |
| Tyler, DS | 1 |
| Lee, CG | 1 |
| Anscher, MS | 1 |
| Ludwig, KA | 1 |
| Seigler, HF | 1 |
| Mantyh, C | 1 |
| Morse, MA | 1 |
| Lockhart, AC | 1 |
| Petros, WP | 1 |
| Honeycutt, W | 1 |
| Spector, NL | 1 |
| Ertel, PJ | 1 |
| Mangum, SG | 1 |
| Hurwitz, HI | 1 |
| Yagyu, T | 1 |
| Aihara, T | 1 |
| Murayama, M | 1 |
| Nakamura, E | 1 |
| Nozaki, H | 1 |
| Niida, M | 1 |
| Yasuoka, H | 1 |
| Nishimoto, Y | 1 |
| Watanabe, Y | 3 |
| Syouda, S | 1 |
| Kouno, T | 1 |
| Fukuhara, A | 1 |
| Nakagawa, K | 1 |
| Nishida, O | 1 |
| Kunii, Y | 3 |
| Hojyo, K | 1 |
| Niimoto, M | 4 |
| Kunitomo, K | 4 |
| Isomoto, H | 1 |
| Ohashi, Y | 1 |
| Yasutomi, M | 1 |
| Emura, T | 1 |
| Suzuki, N | 1 |
| Yamaguchi, M | 5 |
| Ohshimo, H | 1 |
| Fukushima, M | 2 |
| Yamashita, K | 1 |
| Endo, Y | 1 |
| Mai, M | 4 |
| Kamoshida, S | 1 |
| Matsuoka, H | 1 |
| Shimomura, R | 1 |
| Inada, K | 1 |
| Tsutsumi, Y | 1 |
| Basson, MD | 1 |
| Bartoshuk, LM | 1 |
| Dichello, SZ | 1 |
| Panzini, L | 1 |
| Weiffenbach, JM | 1 |
| Duffy, VB | 1 |
| Miyake, K | 1 |
| Hayakawa, K | 1 |
| Nishino, M | 1 |
| Morimoto, T | 1 |
| Mukaihara, S | 1 |
| Mitomi, T | 2 |
| Noto, T | 1 |
| Kumada, K | 2 |
| Hiki, Y | 2 |
| Yamakawa, T | 1 |
| Amano, T | 1 |
| Oki, S | 1 |
| Otani, Y | 2 |
| Takemiya, S | 2 |
| Nishiyama, K | 2 |
| Yamamura, T | 3 |
| Tsuchiya, S | 1 |
| Ogawa, N | 2 |
| Ito, T | 2 |
| Hata, Y | 1 |
| Nakajima, N | 1 |
| Sano, F | 1 |
| Akasaka, Y | 1 |
| Ohmori, K | 1 |
| Okabayashi, K | 1 |
| Hasegawa, H | 2 |
| Kawano, Y | 1 |
| Kawano, S | 1 |
| Nishibori, H | 1 |
| Ishii, Y | 1 |
| Yamauchi, T | 1 |
| Kawano, T | 1 |
| Kitajima, M | 1 |
| Matsuoka, T | 1 |
| Morikage, N | 1 |
| Kobayashi, T | 1 |
| Kuga, T | 1 |
| Nakayama, T | 1 |
| Fujii, Y | 1 |
| Kabashima, A | 1 |
| Sakaguchi, Y | 2 |
| Okita, K | 1 |
| Yamamura, S | 1 |
| Ojima, Y | 1 |
| Nishizaki, T | 1 |
| Tashiro, H | 1 |
| Matsuzaka, T | 1 |
| Asai, K | 1 |
| Fujita, T | 1 |
| Tokuda, E | 1 |
| Hiyoshi, M | 1 |
| Aoki, F | 1 |
| Sugizaki, K | 1 |
| Masaki, Y | 1 |
| Mizushima, T | 1 |
| Mizuno, H | 1 |
| Souma, Y | 1 |
| Kainuma, S | 1 |
| Yamanaka, H | 1 |
| Ozawa, H | 1 |
| Kanou, T | 1 |
| Iwase, K | 1 |
| Lembersky, BC | 3 |
| Wieand, HS | 5 |
| Petrelli, NJ | 1 |
| O'Connell, MJ | 1 |
| Colangelo, LH | 1 |
| Smith, RE | 2 |
| Seay, TE | 1 |
| Giguere, JK | 1 |
| Marshall, ME | 1 |
| Jacobs, AD | 1 |
| Colman, LK | 1 |
| Soran, A | 1 |
| Yothers, G | 2 |
| Wolmark, N | 3 |
| Miyata, K | 1 |
| Izumi, H | 1 |
| Shimomura, K | 1 |
| Matsumura, H | 1 |
| Kakihara, N | 1 |
| Katoh, Y | 1 |
| Ohgaki, M | 1 |
| Iizuka, R | 1 |
| Fujii, K | 1 |
| Shimotsuma, M | 1 |
| Tkenaka, A | 1 |
| Muneoka, K | 1 |
| Shirai, Y | 1 |
| Wakai, T | 1 |
| Yokoyama, N | 1 |
| Sakata, J | 1 |
| Hatakeyama, K | 1 |
| Akita, H | 1 |
| Nakaguchi, K | 1 |
| Kabuto, T | 1 |
| Sato, Y | 2 |
| Inaba, Y | 1 |
| Yamaura, H | 1 |
| Shimamoto, H | 1 |
| Nishiofuku, H | 1 |
| Oyama, T | 1 |
| Sawaki, A | 1 |
| Arai, Y | 1 |
| Segura, C | 1 |
| Afchain, P | 1 |
| de Gramont, A | 1 |
| André, T | 1 |
| Ina, K | 1 |
| Kataoka, T | 1 |
| Ohkita, T | 1 |
| Nagao, S | 1 |
| Ito, A | 1 |
| Inagaki, J | 1 |
| Kato, H | 1 |
| Ando, T | 1 |
| Niwa, Y | 1 |
| Goto, H | 1 |
| Fujie, Y | 1 |
| Seshimo, I | 1 |
| Ezumi, K | 1 |
| Hata, T | 1 |
| Shingai, T | 1 |
| Yasui, M | 1 |
| Takayama, O | 1 |
| Fukunaga, H | 1 |
| Ikenaga, M | 1 |
| Takemasa, I | 1 |
| Yamamoto, H | 2 |
| Ohue, M | 1 |
| Sekimoto, M | 1 |
| Hirota, S | 1 |
| Monden, M | 1 |
| Tetzner, R | 1 |
| Dietrich, D | 1 |
| Distler, J | 1 |
| Temmink, OH | 1 |
| Prins, HJ | 1 |
| van Gelderop, E | 1 |
| Peters, GJ | 5 |
| Kopec, JA | 1 |
| Ganz, PA | 1 |
| Land, SR | 1 |
| Cecchini, RS | 1 |
| Komatsu, Y | 1 |
| Vormittag, L | 1 |
| Kornek, GV | 1 |
| Gruhsmann, B | 1 |
| Lenauer, A | 1 |
| Föger, A | 1 |
| Depisch, D | 1 |
| Lang, F | 1 |
| Scheithauer, W | 1 |
| Katoh, R | 1 |
| Ooshiro, M | 1 |
| Tanaka, F | 1 |
| Fujita, M | 1 |
| Fujita, F | 1 |
| Taguchi, T | 4 |
| Tang, SG | 1 |
| Hornbeck, CL | 1 |
| Byfield, JE | 1 |
| Kuwashima, T | 1 |
| Korematsu, H | 1 |
| Yoshikawa, H | 1 |
| Toyosaki, M | 1 |
| Komi, N | 3 |
| Saito, H | 7 |
| Nakano, K | 5 |
| Toko, T | 2 |
| Takeda, S | 8 |
| Unemi, N | 5 |
| Yuasa, C | 1 |
| Kobayashi, F | 1 |
| Ikeda, T | 2 |
| Sakamoto, N | 1 |
| Kurosaki, M | 1 |
| Tozuka, S | 1 |
| Sakamoto, S | 4 |
| Fukuma, T | 1 |
| Marumo, F | 1 |
| Sato, C | 1 |
| Schmutte, C | 1 |
| Yang, AS | 1 |
| Beart, RW | 1 |
| Jones, PA | 1 |
| Naguib, FN | 1 |
| Hao, SN | 1 |
| el Kouni, MH | 1 |
| Kubota, K | 1 |
| Kajiura, N | 1 |
| Konishi, T | 2 |
| Teruya, M | 1 |
| Tsushima, H | 1 |
| Nakao, K | 1 |
| Arizono, S | 1 |
| Oka, T | 1 |
| Makuuchi, M | 1 |
| Nukatsuka, M | 2 |
| Uchida, J | 4 |
| Oh-ie, S | 1 |
| Nomura, N | 1 |
| Ishitani, K | 1 |
| Baccanari, DP | 1 |
| Davis, ST | 1 |
| Knick, VC | 1 |
| Spector, T | 1 |
| Omura, K | 1 |
| Ishida, F | 1 |
| Yamamitsu, S | 1 |
| Shirasaka, T | 1 |
| Yoshida, Y | 1 |
| Kosaki, G | 1 |
| Kurihara, M | 1 |
| Inada, T | 1 |
| Kubota, T | 1 |
| Ozawa, I | 1 |
| Hishinuma, S | 1 |
| Koyama, Y | 1 |
| Sugimachi, K | 3 |
| Kikuchi, K | 4 |
| Inokuchi, K | 2 |
| Hattori, T | 5 |
| Kondo, T | 2 |
| Abe, O | 2 |
| Uchino, J | 3 |
| Watanabe, H | 2 |
| Sakakibara, N | 1 |
| Iida, A | 1 |
| Komatsu, T | 1 |
| Ookubo, K | 1 |
| Ikeda, N | 1 |
| Asano, M | 1 |
| Yasuno, M | 1 |
| Feliu, J | 1 |
| González Barón, M | 1 |
| Espinosa, E | 1 |
| García Girón, C | 1 |
| de la Gándara, I | 1 |
| Espinosa, J | 1 |
| Colmenarejo, A | 1 |
| Jalón, JI | 1 |
| Fernández, Y | 1 |
| de Castro, J | 1 |
| Tazawa, K | 2 |
| Sakamoto, T | 1 |
| Kuroki, Y | 2 |
| Yamashita, I | 2 |
| Okamoto, M | 2 |
| Katuyama, S | 1 |
| Fujimaki, M | 2 |
| Tsukagoshi, S | 1 |
| Tokunaga, Y | 1 |
| Hata, K | 1 |
| Nishitai, R | 1 |
| Kaganoi, J | 1 |
| Nanbu, H | 1 |
| Ohsumi, K | 1 |
| Mamounas, EP | 3 |
| Jones, J | 1 |
| Wickerham, DL | 2 |
| Holland, SK | 1 |
| Bergman, AM | 1 |
| Zhao, Y | 1 |
| Adams, ER | 1 |
| Pizzorno, G | 1 |
| Pazdur, R | 1 |
| Lassere, Y | 1 |
| Diaz-Canton, E | 1 |
| Ho, DH | 1 |
| Maruyama, M | 1 |
| Kudo, T | 1 |
| Kuwabara, H | 1 |
| Yoshida, T | 1 |
| Sugano, N | 1 |
| Ebuchi, M | 1 |
| van Groeningen, CJ | 3 |
| Pinedo, HM | 2 |
| Idezuki, Y | 1 |
| Haga, S | 1 |
| Ushirokouji, Y | 1 |
| Shibusawa, M | 1 |
| Bandai, Y | 1 |
| Hiraishi, M | 1 |
| Yabe, K | 1 |
| Yumoto, S | 1 |
| Gunji, A | 1 |
| Nishigaki, M | 1 |
| Toh, Y | 1 |
| Oda, S | 1 |
| Yamamoto, N | 1 |
| Smith, R | 1 |
| Colangelo, L | 2 |
| Kralovánszky, J | 1 |
| Katona, C | 1 |
| Jeney, A | 1 |
| Pandi, E | 1 |
| Noordhuis, P | 1 |
| Erdélyi-Tóth, V | 1 |
| Otvös, L | 1 |
| Kovács, P | 1 |
| Van der Wilt, CL | 1 |
| Sato, K | 1 |
| Takechi, T | 3 |
| Tokuda, C | 1 |
| Miyama, Y | 1 |
| Takeda, H | 1 |
| Fukui, H | 1 |
| Nakahara, H | 1 |
| Okajima, M | 1 |
| Nakahara, M | 1 |
| Yano, M | 1 |
| Asahara, T | 1 |
| Ohki, S | 1 |
| Tsukikawa, S | 1 |
| Nagasaki, H | 1 |
| Fukushima, T | 1 |
| Shimada, H | 1 |
| Lin, JK | 1 |
| Wang, WS | 1 |
| Hsieh, RK | 1 |
| Hsu, TC | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Fan, FS | 1 |
| Yen, CC | 1 |
| Lin, TC | 1 |
| Jiang, JK | 1 |
| Yang, SH | 1 |
| Wang, HS | 1 |
| Chen, PM | 1 |
| Goda, F | 1 |
| Wakabayashi, H | 1 |
| Maeba, T | 1 |
| Mori, S | 1 |
| Okano, K | 1 |
| Mihara, T | 1 |
| Fukunaga, M | 1 |
| Okada, H | 1 |
| Ohkawa, M | 1 |
| Maeta, H | 1 |
| Senda, S | 1 |
| Zurita Saavedra, AJ | 1 |
| Navarro Garcia, M | 1 |
| Español, I | 1 |
| Fernández Ortega, A | 1 |
| Akagi, Y | 1 |
| Nozoe, Y | 1 |
| Sasatomi, T | 1 |
| Miyagi, Y | 1 |
| Nakagawa, M | 1 |
| Matono, K | 1 |
| Kobayashi, H | 1 |
| Shirouzu, K | 1 |
| Wilson, RH | 1 |
| Harold, N | 1 |
| Keith, B | 1 |
| Dougherty, DS | 1 |
| Grem, JL | 1 |
| Sanderson, RJ | 1 |
| Bennett, SE | 1 |
| Sung, JS | 1 |
| Mosbaugh, DW | 1 |
| Hardeland, U | 1 |
| Bentele, M | 1 |
| Lettieri, T | 1 |
| Steinacher, R | 1 |
| Jiricny, J | 1 |
| Schär, P | 1 |
| Shibata, M | 1 |
| Nezu, T | 1 |
| Kanou, H | 1 |
| Nagata, Y | 2 |
| Kimura, T | 1 |
| Takekawa, M | 1 |
| Ando, K | 1 |
| Fukuzawa, M | 1 |
| Basaki, Y | 1 |
| Chikahisa, L | 1 |
| Aoyagi, K | 1 |
| Miyadera, K | 1 |
| Yonekura, K | 1 |
| Hashimoto, A | 1 |
| Okabe, S | 1 |
| Wierzba, K | 1 |
| Kuroda, Y | 1 |
| Arima, S | 3 |
| Ohsato, K | 1 |
| Ohkuma, R | 1 |
| Fukuyama, N | 1 |
| Yamanouchi, A | 1 |
| Hisatsugu, T | 1 |
| Abe, R | 1 |
| Chu, E | 1 |
| Chu, MY | 1 |
| Darnowski, JW | 2 |
| Chen, ZH | 1 |
| Pan, BC | 1 |
| Chu, SH | 1 |
| Sakata, Y | 1 |
| Chiba, Y | 1 |
| Kimura, M | 1 |
| Fukushi, G | 1 |
| Matsukawa, M | 1 |
| Wada, K | 1 |
| Aoyama, H | 1 |
| Sawada, Y | 1 |
| Fukushi, M | 1 |
| Wakabayashi, K | 1 |
| Kochi, M | 1 |
| Konomi, K | 1 |
| Yamagata, M | 1 |
| Iwai, S | 1 |
| Tanaka, T | 2 |
| Ochiai, H | 1 |
| Kurokawa, M | 1 |
| Oie, S | 3 |
| Kawaguchi, Y | 1 |
| Yunoki, S | 1 |
| Hizuta, A | 1 |
| Sou, J | 1 |
| Takahashi, M | 1 |
| Yamamoto, M | 1 |
| Kataoka, K | 1 |
| Matumoto, M | 1 |
| Kawaguchi, H | 1 |
| Miyagi, K | 1 |
| Sawa, H | 1 |
| Sakabe, T | 1 |
| Takashima, S | 1 |
| Tomita, F | 1 |
| Gotoda, H | 1 |
| Kinami, Y | 1 |
| Miyazaki, I | 1 |
| Yamaguchi, A | 1 |
| Yoshikawa, K | 1 |
| Iwasaki, T | 1 |
| Amemiya, A | 1 |
| Emoto, T | 1 |
| Han, N | 1 |
| Itou, A | 1 |
| Tsujimura, T | 1 |
| Nakazawa, O | 2 |
| Morita, K | 2 |
| Kure, T | 2 |
| Terada, S | 2 |
| Matsunaga, T | 1 |
| Tsuji, Y | 1 |
| Miyazaki, E | 1 |
| Nakajima, K | 1 |
| Morii, K | 1 |
| Kudo, H | 3 |
| Kuwa, K | 2 |
| Kawasaki, T | 3 |
| Kasahara, N | 3 |
| Okamoto, R | 3 |
| Kawachi, Y | 3 |
| Tominaga, S | 1 |
| Sagara, T | 3 |
| Nyce, J | 1 |
| Klann, RC | 1 |
| Holbrook, CT | 1 |
| Fukamura, T | 1 |
| Umeno, T | 1 |
| Jyozaki, H | 1 |
| Haruta, J | 1 |
| Shimura, H | 2 |
| Ooi, A | 1 |
| Ogino, T | 1 |
| Tsuji, M | 1 |
| Fukada, H | 1 |
| Mori, H | 1 |
| Sugimori, K | 1 |
| Ohyabu, H | 1 |
| Kageyama, T | 1 |
| Sinmyo, K | 1 |
| Hosoi, H | 1 |
| Suwa, H | 1 |
| Kitagawa, M | 1 |
| Yamaguchi, K | 1 |
| Susaki, H | 1 |
| Nio, Y | 1 |
| Imai, S | 1 |
| Shiraishi, T | 1 |
| Ohgaki, K | 1 |
| Tobe, T | 1 |
| McElhinney, RS | 1 |
| McCormick, JE | 1 |
| Bibby, MC | 1 |
| Double, JA | 1 |
| Atassi, G | 1 |
| Dumont, P | 1 |
| Pratesi, G | 1 |
| Radacic, M | 1 |
| Miwa, M | 1 |
| Eda, H | 1 |
| Fukuda, H | 1 |
| Fujimoto, K | 1 |
| Ishitsuka, H | 1 |
| Une, Y | 1 |
| Nagabuchi, E | 1 |
| Kagaya, H | 1 |
| Miyata, S | 1 |
| Yakura, Y | 1 |
| Futami, K | 1 |
| Shigeta, M | 1 |
| Kinashi, M | 1 |
| Nishiyama, M | 3 |
| Niimi, K | 3 |
| Hirabayashi, N | 3 |
| Nosoh, Y | 2 |
| Tohge, T | 1 |
| Anai, H | 1 |
| Kusumoto, H | 1 |
| Masuda, H | 1 |
| Murakami, S | 2 |
| Iwama, T | 1 |
| Yaegashi, K | 1 |
| Mishima, Y | 1 |
| Wang, DC | 2 |
| Toge, T | 1 |
| Kikuchi, R | 1 |
| Ueno, M | 1 |
| Arai, R | 1 |
| Hirayama, M | 1 |
| Terui, T | 1 |
| Fukushi, A | 1 |
| Yoshizaki, N | 1 |
| Nakao, S | 1 |
| Eida, K | 1 |
| Noguchi, K | 1 |
| Yamamoto, Y | 1 |
| Kimoto, M | 1 |
| Kasai, Y | 1 |
| Seo, Y | 1 |
| Nagano, H | 1 |
| Mure, T | 1 |
| Iwamoto, S | 1 |
| Nobutou, H | 1 |
| Sano, K | 1 |
| Tsukada, K | 1 |
| Kameyama, M | 1 |
| Fukuda, I | 1 |
| Furukawa, H | 1 |
| Imaoka, S | 1 |
| Koyama, H | 1 |
| Iwanaga, T | 1 |
| Takagami, S | 1 |
| Saeki, T | 1 |
| Yoshinaka, K | 1 |
| Takahashi, N | 1 |
| Nitta, A | 1 |
| Saitou, T | 1 |
| Mori, Y | 1 |
| Ganes, DA | 1 |
| Wagner, JG | 1 |
| Laurensse, EJ | 1 |
| Lankelma, J | 2 |
| Leyva, A | 1 |
| Handschumacher, RE | 1 |
| Kok, RM | 1 |
| de Jong, AP | 1 |
| Van Way, CW | 1 |
| Reynolds, VH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Randomized, Phase III Study Comparing Trifluridine/Tipiracil in Combination With Bevacizumab to Trifluridine/Tipiracil Monotherapy in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT Study)[NCT04737187] | Phase 3 | 492 participants (Actual) | Interventional | 2020-11-25 | Completed | ||
| Randomized Phase III Trial of Adjuvant Chemotherapy With UFT vs. Observation in Curatively Resected Stage II Colon Cancer[NCT00392899] | Phase 3 | 2,025 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Randomized Phase III Study of UFT+Leucovorin vs. TS-1 as Adjuvant Treatment for Stage III Colon Cancer , and Investigate Predictive Factors Based on Gene Expression[NCT00660894] | Phase 3 | 1,535 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00531245] | Phase 1/Phase 2 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Phase III Randomized Controlled Clinical Study of UFT/LV Therapy Versus UFT/LV + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colorectal Cancer[NCT00497107] | Phase 3 | 300 participants (Anticipated) | Interventional | 2007-07-31 | Recruiting | ||
| A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients With Stages II And III Carcinoma of the Colon[NCT00378716] | Phase 3 | 1,608 participants (Actual) | Interventional | 1997-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Objective response was defined as percentage of participants who achieved complete response (CR) or partial response (PR) according to the RECIST version 1.1 and using investigator's tumour assessment. As per RECIST 1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters. (NCT04737187)
Timeframe: From the date of randomization to the date of documentation of progression or death due to any cause or data cut-off, whichever occurred first (i.e., up to 20 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 6.10 |
| Trifluridine/Tipiracil | 1.22 |
Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. (NCT04737187)
Timeframe: From date of randomization to the death due to any cause or cut-ff date, whichever comes first (maximum duration: up to 20 months)
| Intervention | months (Median) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 10.78 |
| Trifluridine/Tipiracil | 7.46 |
Disease control is defined as percentage of participants who achieved CR or PR, or stable disease (SD) as per RECIST 1.1 and using investigator's tumour assessment from the date of randomization to until disease progression or death due to any cause. As per RECIST 1.1, CR: disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters. PD: at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. (NCT04737187)
Timeframe: From randomization to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (i.e., up to 20 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 69.51 |
| Trifluridine/Tipiracil | 41.87 |
PFS was defined as the time elapsed between the date of randomisation and the date of radiological tumour progression as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by investigator, or death (from any cause), whichever comes first. Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method. (NCT04737187)
Timeframe: From randomization to the date of radiological tumour progression or death due to any cause or data cut-off date whichever comes first (i.e., up to 20 months)
| Intervention | months (Median) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 5.55 |
| Trifluridine/Tipiracil | 2.40 |
Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 12 months was reported. (NCT04737187)
Timeframe: From date of randomization until 12 months post treatment
| Intervention | probability of participants (Number) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 0.43 |
| Trifluridine/Tipiracil | 0.30 |
Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 18 months was reported. (NCT04737187)
Timeframe: From date of randomization until 18 months post treatment
| Intervention | probability of participants (Number) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 0.28 |
| Trifluridine/Tipiracil | 0.15 |
Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 6 months was reported. (NCT04737187)
Timeframe: From date of randomization until 6 months post treatment
| Intervention | probability of participants (Number) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 0.77 |
| Trifluridine/Tipiracil | 0.61 |
An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (time from the first dose of study treatment up to 30 days after the last dose of study treatment). TEAEs included both SAEs and non-SAEs. (NCT04737187)
Timeframe: From Baseline up to 30 days after the last dose of study treatments (i.e., up to 19.5 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAE | TESAE | |
| Trifluridine/Tipiracil | 241 | 77 |
| Trifluridine/Tipiracil + Bevacizumab | 241 | 61 |
PFS was defined as the time elapsed between the date of randomisation and the date of radiological tumour progression as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by investigator, or death (from any cause), whichever comes first. Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method. In this outcome measure, data of PFS at 3 months was reported. (NCT04737187)
Timeframe: From randomization until 3, 6, 9, and 12 months post treatment
| Intervention | probability of participants (Number) | |||
|---|---|---|---|---|
| At 3 Months | At 6 Months | At 9 Months | At 12 Months | |
| Trifluridine/Tipiracil | 0.45 | 0.16 | 0.05 | 0.01 |
| Trifluridine/Tipiracil + Bevacizumab | 0.73 | 0.43 | 0.28 | 0.16 |
19 reviews available for uracil and Colonic Neoplasms
| Article | Year |
|---|---|
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.
Topics: Codon; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Mutation; Proto-Onc | 2022 |
Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Front | 2023 |
A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Folate, genomic stability and colon cancer: The use of single cell gel electrophoresis in assessing the impact of folate in vitro, in vivo and in human biomonitoring.
Topics: Biological Monitoring; Cell Line; Colonic Neoplasms; Comet Assay; DNA Breaks; DNA Methylation; DNA R | 2019 |
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colonic Neoplasms; Colorectal Neoplasms | 2019 |
Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; | 2018 |
Applications of oral fluoropyrimidines in colon cancer: their role and new directions.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Co | 2003 |
[A case of para-aortic lymph node metastasis from colon cancer with complete response to uracil/tegafur plus leucovorin therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Colonic Neoplasms; Humans; Leucovorin; | 2014 |
TAS-102 an Emerging Oral Fluoropyrimidine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2016 |
The role of meta-analysis in cancer clinical trials.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Humans; Meta-Analysis as Topic; Neoplasms; Rectal Neopl | 2009 |
[Chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxy | 2003 |
[Adjuvant treatment of colorectal cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capeci | 2006 |
[Standard chemotherapy for colonic neoplasms].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplas | 2007 |
[Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neopla | 2007 |
UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Colonic Ne | 2007 |
[Fundamental studies on the surgical adjuvant chemotherapy to support the clinical efficacies].
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast N | 1997 |
Uracil-initiated base excision DNA repair synthesis fidelity in human colon adenocarcinoma LoVo and Escherichia coli cell extracts.
Topics: Adenocarcinoma; Aphidicolin; Bacteriophage M13; Cell Extracts; Cell-Free System; Colonic Neoplasms; | 2001 |
Thymine DNA glycosylase.
Topics: Amino Acid Sequence; Animals; Bacterial Proteins; Base Pair Mismatch; Base Sequence; Cell Transforma | 2001 |
35 trials available for uracil and Colonic Neoplasms
| Article | Year |
|---|---|
Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2022 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H | 2022 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H | 2022 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H | 2022 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H | 2022 |
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Ne | 2023 |
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
Topics: Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Epithelial-Mesenchymal Trans | 2019 |
Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2014 |
S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Dru | 2015 |
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2016 |
Folic Acid Supplementation in Postpolypectomy Patients in a Randomized Controlled Trial Increases Tissue Folate Concentrations and Reduces Aberrant DNA Biomarkers in Colonic Tissues Adjacent to the Former Polyp Site.
Topics: Adenomatous Polyps; Aged; Biomarkers; Body Mass Index; Colon; Colonic Neoplasms; Colonoscopy; Comet | 2016 |
Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2012 |
Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Protocols; Colonic | 2012 |
[Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2004 |
Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-flu
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug A | 2005 |
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2006 |
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2006 |
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2006 |
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2006 |
Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2007 |
[Cooperative Study of Surgical Adjuvant Chemotherapy for Colorectal Cancer (fourth report): five-year results after surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 1993 |
[Low-dose cisplatin added to continuous infusion of 5-fluorouracil or oral administration of UFT for inoperable advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Coloni | 1997 |
Postsurgical sequential methotrexate, fluorouracil, and leucovorin for advanced colorectal carcinoma: a preliminary study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 1997 |
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Coloni | 1998 |
[Adjuvant chemotherapy with UFT or UFT with OK-432 to patients with gastric and colorectal cancer. Kanto Adjuvant Study Group].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colo | 1998 |
UFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; | 1999 |
UFT/leucovorin vs 5-FU/leucovorin in colon cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2000 |
[Optimal dosage of UFT in a weekday-on/weekend-off schedule as a postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 2000 |
Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Modalit | 2002 |
[Multicenter cooperative study of pre- and post-operative adjuvant chemotherapy in the treatment of colorectal cancer. North Kyushu Co-operative Study Group for Cancer Chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 1992 |
[Comparative study of UFT plus mitomycin C and UFT plus doxorubicin in adenocarcinoma. Hirosaki Cooperative Group of Cancer Chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Proto | 1992 |
[Clinical effect of postoperative adjuvant chemotherapy for advanced colorectal cancer--comparisons of between tegafur (FT) and UFT].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1991 |
[Cooperative study of surgical adjuvant chemotherapy of colorectal carcinoma (second study): 3-year survival after surgery of non-curatively resected patients. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Drug A | 1989 |
[Clinical trial of UFT in malignancies--an analysis of 337 patients. Co-operative Group for Clinical Study of UFT].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1986 |
165 other studies available for uracil and Colonic Neoplasms
| Article | Year |
|---|---|
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2022 |
The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Liver Neoplasms; Male; Portugal; Prog | 2022 |
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2022 |
Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2022 |
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic | 2022 |
An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; | 2023 |
Benefit of Uracil-Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Colonic Neop | 2022 |
A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
Topics: Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Japan; Retros | 2023 |
Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neo | 2023 |
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro.
Topics: Allografts; Animals; Antineoplastic Agents; Axons; Cell Differentiation; Cell Line, Tumor; Cisplatin | 2020 |
Lonsurf (trifluridine/tipiracil): Assessing the impact of dose related toxicities and progression free survival in (refractory) metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2022 |
Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Co | 2017 |
Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Ne | 2017 |
Reply to P. Di Nardo et al and R. Sun et al.
Topics: Colonic Neoplasms; Double-Blind Method; Drug Combinations; Humans; Pyrrolidines; Thymine; Trifluridi | 2018 |
[A Case of Spontaneous Esophageal Rupture That Required Operation during Adjuvant Chemotherapy for Transverse Colon Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon, Transverse; Col | 2018 |
Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; | 2019 |
[A retrospective study of UFT and oral leucovorin combination adjuvant chemotherapy for patients over 76 years old with stage III colon cancer].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2013 |
[A case of metastatic acsending colon cancer showing sustained complete response to chemotherapy with SOX and followed UFT].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Combinations; Female; | 2013 |
Azoxymethane-induced colon carcinogenesis in mice occurs independently of de novo thymidylate synthesis capacity.
Topics: Animals; Azoxymethane; Carcinogenesis; Choline Deficiency; Colon; Colonic Neoplasms; Crosses, Geneti | 2014 |
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2014 |
Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colonic | 2014 |
Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Combinations; Female; Humans | 2015 |
Reply to the letter to the editor 'Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?' by Abali et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Combinations; Female; Humans | 2015 |
Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
Topics: Animals; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Dideoxyn | 2015 |
Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity.
Topics: Adult; Aged; Amidohydrolases; Antineoplastic Agents; Asian People; Capecitabine; Codon, Nonsense; Co | 2015 |
Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Colonic Neo | 2015 |
[A Case of Ascending Colon Cancer with Extra Iliac Lymph Node Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon, Ascending; Colonic Ne | 2015 |
Adjuvant chemotherapy with tegafur/uracil for more than 1 year improves disease-free survival for low-risk Stage II colon cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2016 |
Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur-Uracil Plus Leucovorin Versus Capecitabine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colo | 2017 |
[A patient in whom oral UFT/Leucovorin therapy proved markedly effective for lung metastasis after surgery for colon cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Human | 2008 |
[A case of simultaneous hepatic metastases of ascending colon cancer responding completely to tegafur/uracil plus oral Leucovorin therapy after primary lesion resection].
Topics: Administration, Oral; Aged, 80 and over; Colonic Neoplasms; Female; Humans; Leucovorin; Liver Neopla | 2008 |
The methylenetetrahydrofolate reductase C677T mutation induces cell-specific changes in genomic DNA methylation and uracil misincorporation: a possible molecular basis for the site-specific cancer risk modification.
Topics: Blotting, Western; Breast Neoplasms; Colonic Neoplasms; CpG Islands; DNA Damage; DNA Methylation; Fo | 2009 |
Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2009 |
The necessity of chemotherapy in T3N0M0 colon cancer without risk factors.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2009 |
[A case of simultaneous bilateral metastatic ovarian tumor of colon cancer followed by FOLFOX4 Regimen and oral tegafur/uracil+oral leucovorin after R0 operation].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colectomy; C | 2009 |
[A case of effective treatment with UFT/LV chemotherapy for para-aortic lymph node metastasis from colonic cancer 8 years after colectomy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2009 |
[A case of fluoropyrimidine-resistant recurrent colon cancer successfully treated with weekly administration of irinotecan].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Coloni | 2010 |
Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Drug C | 2010 |
Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydropyrimidine Dehydrog | 2010 |
Mthfd1 is a modifier of chemically induced intestinal carcinogenesis.
Topics: Aminohydrolases; Animals; Apoptosis; Azoxymethane; Biomarkers, Tumor; Blotting, Western; Carcinogens | 2011 |
[A case of lung metastases of colon cancer demonstrating complete response for more than five years after treatment with UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Femal | 2010 |
Long-term survival results of surgery alone versus surgery plus UFT (Uracil and Tegafur)-based adjuvant therapy in patients with stage II colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neo | 2011 |
[The feasibility of oral fluoropyrimidines as adjuvant chemotherapy after resection and local coagulation therapy of colorectal liver metastases].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2011 |
[A case of pathological complete response after treatment with uracil/tegafur (UFT) and folinate (Leucovorin) for liver metastasis of colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Female | 2011 |
[A case of laparoscopic radiofrequency ablation for liver metastatic tumor from colorectal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colonic Neoplasms; Female; | 2011 |
[A case of lung metastases after surgery for colon cancer demonstrating complete response for more than six years after treatment with UFT/LV].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Humans; Leucovorin; Lung | 2011 |
[Marked response to oral administration of UFT and leucovorin for liver metastases from colon cancer in an elderly patient].
Topics: Administration, Oral; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 2012 |
[A retrospective study of UFT and oral leucovorin plus PSK combination adjuvant chemotherapy in patients with stage III colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Leucovori | 2012 |
[A case of stage IV colon cancer effectively treated with tegafur uracil/calcium folinate in a patient on hemodialysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; Combined Modality Ther | 2012 |
Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; D | 2002 |
[A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Col | 2002 |
[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2002 |
Therapy-related erythroleukemia caused by the administration of UFT and mitomycin C in a patient with colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, | 2003 |
NICE recommends new treatment for breast and bowel cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2003 |
Comparison of 5-fluorouracil and 5-fluoro-2'-deoxyuridine in the treatment of far-advanced breast and colon lesions.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Deoxyuridine; Fluorouracil; Humans; Nucl | 1962 |
5-Fluorouracil in the treatment of inoperable carcinoma of the colon and rectum.
Topics: Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms; Rectum; | 1962 |
[NEW ANTIBLASTIC AGENTS].
Topics: Antineoplastic Agents; Colonic Neoplasms; Ethoglucid; Fluorouracil; Neoplasm Metastasis; Neoplasms; | 1963 |
DEOXYRIBOSYL TRANSFER. I. THYMIDINE PHOSPHORYLASE AND NUCLEOSIDE DEOXYRIBOSYLTRANSFERASE IN NORMAL AND MALIGNANT TISSUES.
Topics: Animals; Breast Neoplasms; Carcinoma; Carcinoma, Ehrlich Tumor; Cattle; Colonic Neoplasms; Cricetina | 1964 |
[A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 2003 |
[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Coloni | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
Oral administration of uracil-tegafur (UFT) inhibits liver micrometastasis of human colon cancer in an orthotopic nude mouse model and its early detection system.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2004 |
Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; C | 2004 |
Association between 6-n-propylthiouracil (PROP) bitterness and colonic neoplasms.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Chi-Square Distribution; Cohort Studies; Colonic N | 2005 |
Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square | 2005 |
[A case of colorectal cancer effectively treated with UFT/LV].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Mo | 2005 |
[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colect | 2005 |
[Efficacy of tegafur/uracil plus oral leucovorin therapy for advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2005 |
[A case of multiple hepatic and peritoneal metastases from colon cancer responding to oral UFT+leucovorin chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Col | 2005 |
[A case of recurrent colon cancer responding completely to uracil/tegafur (UFT) plus oral leucovorin (LV) therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; | 2005 |
[Efficacy of the combined use of taurine for hyperbilirubinemia caused by UFT therapy after surgery for colonic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Dr | 2006 |
[Second-line chemotherapy with pharmacokinetic modulating chemotherapy for unresectable colorectal carcinoma recurrences resistant to 5-FU-based chemotherapy].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co | 2006 |
[Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neop | 2006 |
[Retrospective analysis of tegafur/uracil (UFT) plus oral leucovorin (LV) regimen in patients with advanced colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
[Two metastatic colonic cancer patients successfully treated by combination therapy of tegafur/uracil (UFT) and oral Leucovorin].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colon, S | 2006 |
Complete response of highly advanced colon cancer with multiple lymph node metastases to irinotecan combined with UFT: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Col | 2006 |
Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA.
Topics: Colonic Neoplasms; DNA; DNA Methylation; DNA, Neoplasm; Female; Humans; Male; Polymerase Chain React | 2007 |
The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Topics: Administration, Oral; Animals; Apoptosis; Capecitabine; Cell Cycle; Cell Line, Tumor; Colonic Neopla | 2007 |
UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 2007 |
Enhancement of antitumor effect of tegafur/uracil (UFT) plus leucovorin by combined treatment with protein-bound polysaccharide, PSK, in mouse models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Colonic Neoplasms; Disease Models, Animal; Dr | 2007 |
[Experimental chemotherapy of human gastrointestinal and breast cancers in nude mice and its correlation to clinical effect].
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 1984 |
Enhanced accumulation of 5-fluorouracil in human tumors in athymic mice by co-administration of Ftorafur and uracil.
Topics: Animals; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Mice; Mice, Nude; Neopl | 1984 |
[Clinical trial of UFT in recurrent or advanced cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 1982 |
[Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--growth-inhibitory activity of combination against human tumor xenograft].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1995 |
[Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopla | 1995 |
Severe chronic active hepatitis induced by UFTR containing tegafur and uracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chemic | 1995 |
Base excision repair of U:G mismatches at a mutational hotspot in the p53 gene is more efficient than base excision repair of T:G mismatches in extracts of human colon tumors.
Topics: Base Sequence; Colonic Neoplasms; Deoxyribonuclease (Pyrimidine Dimer); DNA Glycosylases; DNA Repair | 1995 |
Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil.
Topics: Animals; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NAD+); Drug Synergism; Female; Fluorouracil | 1994 |
Effects of preoperative chemotherapy on DNA ploidy patterns, cell cycle, and histological findings in gastric and colonic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Chemothe | 1994 |
[Antitumor and anticachectic activity of UFT in BALB/c mice bearing colon 26 adenocarcinoma].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cachexia; Colo | 1994 |
5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.
Topics: Administration, Oral; Animals; Biological Availability; Colonic Neoplasms; Dihydrouracil Dehydrogena | 1993 |
[Clinical efficacy of cis-diamminedichloroplatinum [II] and 5-fluorouracil (UFT) in advanced cancer of the alimentary tract].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1993 |
[A comparison of 5-fluorouracil concentration of 5-fluorouracil drip infusion versus orally UFT in plasma of same patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 1993 |
Effect of 5-fluorouracil and UFT on experimental liver metastasis model of colorectal cancer using mouse colon 26 cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Combinations; Drug | 1993 |
A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Animals; Colonic Neoplasms; Fluorouracil; Gastrectomy; Humans; | 1993 |
[Evaluation of long-term administration of oral anti-cancer agent].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 1993 |
[A case of advance colon cancer responding to sequential methotrexate and 5-fluorouracil therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 1993 |
[Prolongation of survival and antitumor activity of antitumor drugs in murine cancer cachexia model].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Colonic Neoplasms; Dinoprostone; | 1996 |
Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Antidotes; Antimetabolites, Antineop | 1997 |
Inhibitory effects of fluorinated pyrimidines, 5'-DFUR, UFT and T-506, in a model of hepatic metastasis of mouse colon 26 adenocarcinoma-assessment of inhibitory activity and adverse reactions at the maximum tolerated dose.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Colonic Neoplasms; Dose-Response Relati | 1997 |
Future directions in the adjuvant treatment of colon cancer.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms | 1997 |
19F NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine.
Topics: Animals; Colonic Neoplasms; Enzyme Inhibitors; Fluorine Radioisotopes; Fluorouracil; Magnetic Resona | 1997 |
[Preoperative chemotherapy for advanced colorectal carcinomas--comparison of histological effect between UFT + leucovorin tablet and UFT alone].
Topics: Administration, Oral; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopl | 1998 |
Dihydropyrimidine dehydrogenase in livers from mouse and rat, and in human liver, colon tumors, and mucosa in relation to anabolism of 5-fluorouracil.
Topics: Animals; Biological Availability; Biotransformation; Colonic Neoplasms; Dihydrouracil Dehydrogenase | 1998 |
Induction of apoptosis in human tumour xenografts after oral administration of uracil and tegafur to nude mice bearing tumours.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Division; Colonic Neoplasms; Ga | 1998 |
5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Colonic Neoplasms; Deoxyuridine; Dose-Re | 1999 |
Experimental postoperative adjuvant chemotherapy by UFT using primary tumor amputation model.
Topics: Amputation, Surgical; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinom | 2000 |
[Antitumor activity of 1-hexylcarbamoyluracil which is carmofur substituted fluorine for hydrogen].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Mice; Mice, Inbred BALB C; | 2000 |
[A case report of unresectable colon cancer that disappeared following pharmacokinetic modulation chemotherapy (PMC)].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 2000 |
[Three cases of liver metastasis of colon cancer responding to systemic combination chemotherapy utilizing CPT-11].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2000 |
Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2000 |
[Outcomes of home anti-cancer chemotherapy--estimation of hepatic arterial infusion chemotherapy for patients with multiple liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Fluorouracil; He | 2000 |
UFT-induced haemolytic anaemia.
Topics: Aged; Aged, 80 and over; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Colonic | 2001 |
[Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Combinations; Drug Screening Assays, Antitum | 2001 |
Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Colonic Neoplasms; Dihydrouracil | 2001 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
Enhancement of 5-fluoro-2'-deoxyuridine antineoplastic activity by 5-benzyloxybenzyloxybenzylacyclouridine in a human colon carcinoma cell line.
Topics: Antimetabolites, Antineoplastic; Cell Division; Cell Line; Colonic Neoplasms; Deoxyuridine; DNA Repl | 1992 |
[A case of colon cancer with severe anal bleeding caused in a preoperative chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Adult; Anal Canal; Antineoplastic Combined Chemotherapy Protoc | 1991 |
[Antitumor activity of T-506, a novel synthetic FUDR derivative, on murine colon cancer and its hepatic metastasis].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; F | 1991 |
[Combination chemotherapy with orally administered UFT and leucovorin (LV)].
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemot | 1991 |
[Effect of UFT by oral administration using a murine hepatic metastasis model].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Hu | 1991 |
[Study of pre-operative chemotherapeutic methods for colonic cancer--the concentration in blood and tissues after pre-operative administration of UFT].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 1991 |
[Treatment with UFT as surgical adjuvant chemotherapy in carcinoma of large intestine. Cooperative Study Group of Surgical Adjuvant Chemotherapy for Colorectal Cancer in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedule; Hum | 1990 |
[Analysis of the mechanism of increased antitumor activity of UFT after combined treatment with CDDP].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasm | 1990 |
[Experimental study of the effect of combined treatment of UFT with CDDP on human solid tumor-xenografts in nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cisplatin; | 1990 |
[Tissue UFT distribution and histological changes following UFT administration in metastatic liver cancer cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Human | 1990 |
[Combination chemotherapy of UFT with adriamycin (ADM) and cisplatin (CDDP) for advanced gastrointestinal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Col | 1990 |
[Effects of hyperthermochemotherapy on activities of DNA-synthesizing enzymes in 1, 2-dimethylhydrazine (DMH)-induced colon carcinomas in rats].
Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colo | 1990 |
Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells.
Topics: Adenocarcinoma; Carbon Radioisotopes; Colonic Neoplasms; Dehydroepiandrosterone; Fluorouracil; Human | 1990 |
[Study of tissue drug concentration of fluorinated pyrimidine anticancer drugs--comparison of 5'DFUR and UFT].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colon; Colonic Neoplasms; Dru | 1990 |
The effect of UFTM therapy on primary and metastatic colon cancer from the same human xenotransplanted into nude mice.
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colo | 1990 |
[An autopsy study of immunoblastic lymphadenopathy (IBL)-like T-cell lymphoma in a patient previously treated with chemotherapy in colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 1989 |
[Influence of OK-432 on intratumor 5-fluorouracil concentration in cases given UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Biotransformation; Colonic Neop | 1989 |
[Anti-tumor effect of fluoropyrimidines on human tumor cell lines transplanted in nude mice with CCl4-induced liver dysfunction].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbon Tetrachloride; Cell Line; Colonic Ne | 1989 |
Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Chemical Phenomena; Chemistry; Colonic Neo | 1989 |
[Comparative studies on the antitumor activity of the fluorinated pyrimidines 5'-DFUR, tegafur, UFT and FUra on various murine tumors].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Floxuridine; Fluorouraci | 1988 |
[Effects of preoperative administration of UFT in gastrointestinal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Humans; Kine | 1986 |
[5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Male; Rats | 1986 |
[In vivo chemosensitivity test for UFT and FT-207. I--Subrenal capsule assay].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colonic Neopla | 1987 |
[Chemosensitivity testing for 5-FU and 5-FU derivatives using subrenal capsule assay].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Units Assay; Fluor | 1987 |
Thymidylate synthetase and thymidine kinase activities in DMH-induced colon carcinomas in rats and effects of UFT.
Topics: 1,2-Dimethylhydrazine; Animals; Antineoplastic Combined Chemotherapy Protocols; Colon; Colonic Neopl | 1986 |
[In vivo chemosensitivity test for UFT and FT-207. II. Chemosensitivity test on human tumor xenografts transplanted in nude mice].
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Animals; Antineoplastic Combined Chemotherapy Protocols; | 1987 |
[Effect of combination of UFT and MMC (UFT-M therapy) on human colonic cancer xenotransplanted into nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colonic Neoplasms; Drug Admi | 1987 |
[Combination chemotherapy of UFT with adriamycin in advanced gastrointestinal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Colonic Neopla | 1987 |
[The effect of UFT on lymphocyte subsets and lymphocyte response to PHA].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Humans; Immunocompetence; Lymphoc | 1987 |
[The effect of UFT on thymidine kinase and thymidylate synthetase activities and autoradiograph in DMH-induced colon cancer in rat].
Topics: 1,2-Dimethylhydrazine; Animals; Antineoplastic Combined Chemotherapy Protocols; Autoradiography; Col | 1987 |
[A case of colon cancer with pulmonary metastasis treated effectively by uracil futraful].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Humans; L | 1988 |
[Effects of SSM (purified polysaccharides from human tubercle bacillus, maruyama vaccine) and UFT (a combination of tegafur and uracil) on DNA-synthesizing enzyme activities in 1,2-dimethylhydrazine (DMH)-induced rat colon carcinomas].
Topics: 1,2-Dimethylhydrazine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 1987 |
[A case of colorectal cancer showing complete response to UFT].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined M | 1988 |
Combined effects of UFT with other anticancer agents using in vivo chemosensitivity tests.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Transformed; Colonic Neoplasms; | 1988 |
[The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci | 1988 |
[Effect of UFTM therapy on primary and metastatic colon cancer of human xenotransplanted in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Hu | 1988 |
Improved high-performance liquid chromatographic assay for the quantification of 5-bromo-2'-deoxyuridine and 5-bromouracil in plasma.
Topics: Aged; Bromodeoxyuridine; Bromouracil; Chromatography, High Pressure Liquid; Colonic Neoplasms; Human | 1988 |
Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.
Topics: Animals; Body Temperature; Brain; Colonic Neoplasms; Cytidine; Cytidine Deaminase; Dose-Response Rel | 1987 |
Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine.
Topics: Animals; Colonic Neoplasms; Female; Fluorouracil; Lethal Dose 50; Mice; Mice, Inbred C57BL; Uracil; | 1985 |
Highly sensitive determination of 5-fluorouracil in human plasma by capillary gas chromatography and negative ion chemical ionization mass spectrometry.
Topics: Alkylation; Bromouracil; Colonic Neoplasms; Fluorouracil; Gas Chromatography-Mass Spectrometry; Huma | 1985 |
A new method for treatment of carcinoma of the breast and colon with 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Chemical Phenomena; Chemistry; Colonic Neoplasms; Female; Fluorouraci | 1970 |